

Curriculum Vitae Dr Brenda Hemmelgarn

August 15 2015

I. Biographical Data:

Name: **Brenda R Hemmelgarn**
Address: 3rd Floor TRW Building, Room 3D10
3280 Hospital Drive NW
Calgary, Alberta, Canada
T2N 4Z6
Telephone: (403) 210-7065

Present rank: Professor
Department: Community Health Sciences
Medicine

Faculty: Cumming School of Medicine
Institution: University of Calgary

II. Academic Record:

Final degree: FRCP(C)
Date completed: September, 2003
Specialty: Nephrology
Institution: University of Calgary, Alberta Canada

i. Undergraduate:

Doctor of Medicine (1995 - 1998), McMaster University, Hamilton Ontario
Bachelor of Science in Nursing (1986 – 1988). Great Distinction
University of Saskatchewan, Saskatoon Saskatchewan
Diploma Nursing (1982 – 1984), Kelsey Institute, Saskatoon SK

ii. Special Professional:

Nephrology Fellowship (July 2001 – June 2003)
University of Calgary, Calgary Alberta

General Internal Medicine Residency (July 1998 – June 2001)
University of Calgary, Calgary Alberta
Fellow of the Royal College of Physicians and Surgeons of Canada

iii. Graduate and post-doctoral:

Doctor of Philosophy (1991 – 1997)
Dept of Epidemiology and Biostatistics

McGill University, Montreal, Quebec, Dean's Honour List
 Master of Nursing (1988 – 1990)
 University of Saskatchewan, Saskatoon Saskatchewan

iv. Licensure, certification and boards:

1999 Licensee of the Medical Council of Canada (LMCC)
 2002 Fellow of the Royal College of Physicians and Surgeons of Canada,
 FRCP(C), General Internal Medicine
 2003 Fellow of the Royal College of Physicians and Surgeons of Canada,
 FRCP(C), Nephrology

III. Awards and Distinctions

2014 Research Preceptor Award - Dept of Medicine, University of Calgary
 Distinguished Achievement Award for preceptorship in research to trainees
 2013 Dept of Medicine Team Builder of the Year Award, U of Calgary
 Outstanding contributions in leadership
 2013 Associate Dean's Letter of Excellence for Teaching Excellence
 University of Calgary
 2013 Killam Research Leader Award
 University of Calgary
 (For outstanding contributions to research, international leadership and the
 the distinction earned for the University of Calgary)
 2013 Top Achievements in Health Research
 Canadian Institutes of Health Research (CIHR) and the Canadian Medical
 Association Journal (CMAJ)
 (One of the top Canadian achievements in health research)
 2012 Royal College of Physicians and Surgeons of Canada
 Royal College Medal Award in Medicine
 2012 Distinguished Scientist Research Award
 Hypertension Canada
 2012 President's Excellence Award for Outstanding Achievements in Research
 Alberta Health Services
 2012 Fellowship – Canadian Academy of Health Sciences
 For leadership, distinctive competencies and commitment to advance
 academic health sciences
 2011 Dept of Medicine Dr John M Conly Innovation Award
 Significant contribution that has led to an innovation in medical treatment,
 practice or service: Siksika outreach clinic
 2011-2016 Roy and Vi Baay Chair in Kidney Research
 Faculty of Medicine, University of Calgary
 2009 Research Preceptor Award - Dept of Medicine, University of Calgary
 Distinguished Achievement Award for preceptorship in research to trainees
 2008 – 2012 Alberta Heritage Foundation for Medical Research
 Population Health Investigator Award - Renewal
 2007 Cochrane Distinguished Achievement Award
 Faculty of Medicine, University of Calgary

2006	Distinguished Achievement Award for excellence in research Canadian Society for Clinical Investigation 2006 Joe Doupe Young Investigator Award (Outstanding research accomplishments in first 5 years of career)
2005 – 2008	Alberta Heritage Foundation for Medical Research Population Health Investigator Award
2005 – 2010	Canadian Institutes of Health Research New Investigator Award
2005 – 2007	Kidney Foundation of Canada Biomedical Scholarship (declined for CIHR New Investigator Award)
2004	Petro-Canada Young Innovator Award in Community Health

Nephrology Fellowship, University of Calgary

2001	“Clerkship Award for Excellence in Teaching” Undergraduate Medical Education, University of Calgary
2001	“Outstanding Contribution to Resident Education” Faculty of Medicine Award, University of Calgary

Internal Medicine Residency, University of Calgary

2000 – 2001	Chief Medical Resident Department of Medicine, University of Calgary, Calgary, Alberta
-------------	---

Doctor of Philosophy, McGill University

1992 – 1995	National Health PhD Fellowship National Health Research and Development Program (NHRDP)
1992	MRC Graduate Fellowship Medical Research Council of Canada, Ottawa, ON
1991	Max Binz Fellowship Graduate Scholarship for Academic Excellence McGill University, Montreal, Quebec

Master of Nursing

1989 – 1990	University of Saskatchewan Graduate Scholarship University of Saskatchewan, Saskatoon, Saskatchewan
1988 – 1989	University of Saskatchewan Graduate Scholarship University of Saskatchewan, Saskatoon, Saskatchewan

IV. Academic Appointments

2014 (Oct) – current	Head, Department of Community Health Sciences
2013 – current	Professor. Department of Medicine, Faculty of Medicine, University of Calgary
2013 – current	Professor. Department of Community Health Sciences, Faculty of Medicine, University of Calgary (joint appointment)
2008 – 2013	Associate Professor. Department of Medicine, Faculty of Medicine, University of Calgary
2008 – 2013	Associate Professor. Department of Community Health Sciences, Faculty of Medicine, University of Calgary (joint appointment)

2003 – 2008	Assistant Professor. Department of Medicine, Faculty of Medicine, University of Calgary
2003 – 2008	Assistant Professor. Department of Community Health Sciences, Faculty of Medicine, University of Calgary (joint appointment)

V. Educational Activities

i. Undergraduate:

2005 – current	Lecturer – Renal Course for 1 st year medical students Hypertension – epi and treatment (3 hours lecture/year)
2002 - current	Small group teaching for Renal course for 1 st year medical students University of Calgary medical school Approximately 12 hours contact time per year
2001 – current	Examiner for Clinical Clerk OSCE examinations

Summer Student Supervision

Megan Manning	Alberta Innovates Health Solutions Summer Student 2010
---------------	--

ii. Graduate:

2009 - current	Course Coordinator MDSC 645.18 “Foundations in Health Services Research” Community Health Sciences Graduate Level Course
2006 - current	Co-instructor MDSC 755.84, Systematic Reviews Community Health Sciences Graduate level course
2007 - 2013	Co-instructor MDSC 647.15, Clinical Epidemiology Community Health Sciences Graduate level course

Graduate Students Supervised – Primary Supervisor

Katherine Gooch	Master’s student, Master’s of Applied Epidemiology Curtin University of Technology (2003-2005) <i>NSAIDS and progression of chronic kidney disease</i>
Song Gao	Master’s student, Department of Community Health Sciences University of Calgary (2004 - 2006) <i>Chronic kidney disease among First Nations in Alberta: Prevalence and access to care</i>
Marc Deyell	Master’s student, Department of Community Health Sciences University of Calgary (2005 – Nov 2008) <i>The optimal timing of coronary artery bypass grafting following non-ST elevation myocardial infarction</i> Awards: Department of Medicine Scholarship (2005-2006).
Paul Ronksley	Master’s student, Department of Community Health Sciences University of Calgary (2006 - 2008) <i>Association between severity of OSA and health care utilization</i> Awards: Achievers in Medical Science Graduate Scholarship (2008)

Lianne Barnieh	<p>PhD student, Department of Community Health Sciences University of Calgary (2006 - 2010)</p> <p><i>A patient centered educational intervention to improve living kidney donation: a randomized controlled trial</i></p> <p>Awards: Kidney Foundation of Canada Scholarship (2006-2009)</p>
Matthew James	<p>PhD student, Department of Community Health Sciences University of Calgary (2007 - 2010)</p> <p><i>Contrast induced nephropathy and progression of kidney disease after coronary angiography</i></p> <p>Awards: AHFMR Clinical Research Scholarship (2007-2010) KFOC - KRESCENT Post Doctoral Fellowship (2007-2010) Queen Elizabeth Post Graduate Scholarship (2010) J.B. Hyne Research Innovation Award (2010) Izaak Walton Killam Pre Doctoral Scholarship (2010)</p>
Vinay Deved	<p>Master's student, Department of Community Health Sciences University of Calgary (2008 - 2012)</p> <p><i>Quality of care and outcomes for First Nations with diabetes</i></p> <p>Awards: AHFMR Clinical Fellowship (2009-2011)</p>
Paul Ronskley	<p>PhD student, Department of Community Health Sciences University of Calgary (2008 -2013)</p> <p><i>Unmet health care needs for patients with chronic disease</i></p> <p>Awards: Queen Elizabeth II Doctoral Graduate Scholarship (2009) CIHR Frederick Banting and Charles Best Scholarship (2008) Dean's Publication and Mentorship Prize (2012) CIHR Postdoctoral Fellowship Award (2013)</p>
Rob Weaver	<p>MSc student, Department of Community Health Sciences University of Calgary (2010 -2013)</p> <p><i>An outcome evaluation of the diabetes education component of the Living Well Program</i></p> <p>Awards: Western Regional Training Centre (2010-2012)</p>
Helen Tam-Tham	<p>PhD student, Department of Community Health Sciences University of Calgary (2013 -)</p> <p><i>Implementation and evaluation of a clinical pathway for CKD</i></p> <p>Awards: AI-HS Fellowship (2015-2017) AIHS CRIO Team Grant Trainee Award (2014-2015) Western Regional Training Centre (2013-2014) Achievers in Medical Sciences Award (2013-2014) Student Doctoral Scholarship (2013-2014)</p>

Warren Veale Doctoral Entrance Scholarship (2013-2014)

- James Wick MSc student, Department of Community Health Sciences
University of Calgary (2013 -)
Awards: Western Regional Training Centre (2013-2014)
Alberta Innovates Health Solutions Scholarship (2014-2015)
- Nathalie Saad MSc student, Department of Community Health Sciences
University of Calgary (2013 -)
Awards: Roy & Vi Baay Chair in Kidney Research Scholarship (2013-2015)
- Lauren Galbraith MSc student, Department of Community Health Sciences
University of Calgary (2014 -)
Implementation of a nurse-led anemia protocol for hemodialysis patients
Awards: KT Canada Scholarship (2014-2015)
CIHR Canada Graduate Scholarship (2015-2016)
- Meghan Elliott MSc student, Department of Community Health Sciences
University of Toronto (2014 -) Co-supervisor with Dr Sharon Straus
Awards: Alberta Innovates Health Solutions (2014-2016)

Graduate Students Supervised – Committee Member

- Susan Quach Master's student, Department of Community Health Sciences
University of Calgary (2006 - 2008)
- Emmanuel Ngwakongnwi PhD student, Department of Community Health Sciences
University of Calgary (2007 - 2011)
- Jie Gao PhD student, Department of Computer Science
University of Calgary (2006 - 2012)
- Valerie Kiss Master's student, Department of Community Health Sciences
University of Calgary (2007 - 2010)
- Pietro Ravani PhD student, Department of Epidemiology and Biostatistics
Memorial University, Newfoundland (2005 - 2009)
- Billie-Jean Martin PhD student, Department of Community Health Sciences
University of Calgary (2008 - 2012)
- Ghazwan Altabbaa Master's student, Department of Community Health Sciences
University of Calgary (2008 - 2012)

Olesya Elikan	Master's student, Department of Geography University of Calgary (2008 - 2010)
Lawrence Korngut	Master's student, Department of Community Health Sciences University of Calgary (2009 - 2013)
Andrea Soo	PhD student, Department of Community Health Sciences University of Calgary (2009 - 2015)
Olesya Elikan	PhD student, Department of Geography University of Calgary (2011 -)
Peter Rymkiewicz	MSc student, Department of Community Health Sciences University of Calgary (2011 - 2015)
Daniel Niven	PhD student, Department of Community Health Sciences University of Calgary (2012 -)
Jodie Roberts	MSc student, Department of Community Health Sciences University of Calgary (2012 -2014)

Thesis External Examiner

Rizwan Shahid	Master of GIS, Dept of Geography, 2005. University of Calgary
Dean Eurich	PhD Dept of Public Health Sciences, 2007 University of Alberta
Meghan Sebastianski	PhD Dept of Public Health Sciences, 2014 University of Alberta

PhD Candidacy Examination

Dean Eurich	PhD, Dept of Public Health Sciences, 2006 University of Alberta
Jie Gao	PhD, Department of Computer Science, 2006 University of Calgary
Cathy Eastwood	PhD, Faculty of Nursing, 2012 University of Calgary
Derik Roberts	PhD, Dept of Community Health Sciences, 2013 University of Calgary

iii. Postgraduate:

2003 – current	Course Coordinator for Nephrology Fellows Academic Half-day “Chronic Renal Failure”
2008 - current	Member, KRESCENT Curriculum Committee Canadian Society of Nephrology / CIHR post graduate training program for kidney research

2007 - current Co-director, Dept of Medicine, Internal Medicine Resident Research Committee

2007 – 2009 TORCH Mentor (Tomorrow's Research Cardiovascular Health Professionals)

Post-graduate Supervision

Research preceptor - Dr Laura Gregor, nephrology fellow (2003-2004)
- Dr Chandra Thomas, nephrology fellow (2003-2006)
- Dr Sophia Chou, nephrology fellow (2003-2006)
- Dr Matt James, internal medicine resident (2004 – 2007)
- Dr Mike Walsh, nephrology fellow (2004 – 2007)
- Dr Penelope Pooyah, nephrology fellow (2006 – 2008)
- Dr Vinay Deved nephrology fellow (2006 – 2008)
- Dr Joslyn Conley, internal medicine resident (2006 – 2011)
- Dr Jennifer Grossman, internal medicine resident (2006 – 2010)
- Dr Meredith Borman, internal medicine resident (2006 – 2009)
- Dr Ben Thomson, internal medicine resident (2007 – 2010)
- Dr Davina Tai, nephrology fellow (2007 – 2012)
- Dr Jay Hochman, internal medicine resident (2008 – 2010)
- Dr Louis Girard, nephrology fellow (2008 – 2010)
- Dr Meghan Elliott, internal medicine resident (2008 – current)
- Dr David Ward, internal medicine resident (2009 – current)
- Mr Tyrone Harrison, medical student (2012 – current)

Post-Doctoral Students Supervised – Primary Supervisor:

Susan Samuel Post-Graduate Trainee, Department of Medicine
University of Calgary (2007 - 2009)

TC Turin Post-doctoral student, Department of Medicine
University of Calgary (March 2010 – Sept 2012)

Lauren Bresee Post-doctoral student, Department of Medicine
University of Calgary (Aug 2010 – Nov 2012)

Min Jun Post-doctoral student, Department of Medicine
University of Calgary (March 2013 – current)

Faculty Mentor

Dr Charlene Fell University of Calgary (2008 -)
Dr Susan Samuel University of Calgary (2009 -)
Dr Mitesh Thakrar University of Calgary (2011 -)
Dr Matthew James University of Calgary (2011 -)
Dr Cheryl Barnabe University of Calgary (2011 -)
Dr TC Turin University of Calgary (2012 -)

VI. Administrative Responsibilities

i. Departmental:

2000 – 2001	Chief Resident, Department of Medicine, University of Calgary
2003 –2009	Assistant Program Director, Division of Nephrology Training Committee
2003 – 2012	Director, Research, Division of Nephrology Fellowship Training Committee
2003 – current	Chair, Division of Nephrology Research Group
2004 - current	Director, Alberta Kidney Disease Network
2005– 2010	Member, Internal Medicine Resident Research Committee
2006 – 2010	Co-chair, Electronic Data Capture Working Group, U of C
2007 – 2009	Co-chair, Internal Medicine Resident Research
	Co-chair, Division of nephrology Innovation Program

ii. Faculty / University:

2008 – current	Research Award Committee
2009	External Reviewer, Department of Family Medicine Research
2009	Member, Search and Selection Committee, Institute of Population and Public Health
2010	Member, Search and Selection Committee, Associate Dean Faculty Assessment and Development
2010	Member, Scientific Ad Committee, UofC Faculty of Medicine Team Grant Competition
2011 – current	Member, Libin Cardiovascular Institute Community Interaction Committee
2011	Faculty Council Elected Member, Faculty Promotions Committee, UofC Faculty of Medicine
2012 – current	Member, Libin Cardiovascular Institute Research Executive Committee (develop strategic focus for research activities in the Libin CVI)
2015	Member, Ministerial Health Research Task Force – to advise the Minister on Health on Research Alignment for the Province

VII. Professional Activities

i. Membership in professional and learned societies

2002 – current	Alberta Medical Association
	Canadian Medical Association
	College of Physicians and Surgeons of Alberta
	Royal College of Physician and Surgeons
	Canadian Society of Hypertension

ii. Professional service

2002 – 2012	Central Review Committee of the Canadian Hypertension Education Program Task force. Develop hypertension guidelines (Chair 2006-2010)
2005 – 2010	Member of the Canadian Organ Replacement Register (CORR) Advisory Committee.
2005 - 2015	Steering Committee Member – Alberta Diabetes Surveillance System.
2006 – 2010	Alberta Heritage Foundation for Medical Research – Program Advisory Committee.

2008 – current	Kidney Foundation of Canada, S AB Branch – Board of Directors
2008 – 2015	Canadian Society of Nephrology, Clinical Practice Guideline Committee
2009 – 2012	Alberta Heritage Foundation for Medical Research – Clinical Trainee Advisory Committee.
2010 – 2014	Kidney Disease Improving Global Outcomes (KDIGO) Implementation Task Force
2010 – 2012	KDIGO CKD Clinical Practice Guidelines development
2010 – 2014	Chair, Canadian Society of Nephrology, Chair, Clinical Practice Guideline Committee
2010 – 2014	Canadian Organ Replacement Register, Board of Directors.
2010 – 2013	Chronic Kidney Disease – Prognosis Consortium, Steering Committee
2011 – 2012	Planning committee member, National Kidney Foundation Spring Clinical Meetings
2010 – 2011	Co-Chair, Abstract Committee, World Congress of Nephrology
2011 – 2013	Co-Chair, CKD Theme, Scientific Program Committee, World Congress of Nephrology, Hong Kong 2013
2012 – 2014	Board of Directors, Hypertension Canada
2012 – 2015	CIHR Institute Advisory Board Institute of Infection and Immunity
2012 – 2013	CIHR Interdisciplinary Adjudication Committee Review of Canada Research Chairs for funding decisions
2012 – current	Knowledge Translation Canada – A National Research Network (CIHR/CFI) Calgary Node Member
2010 – current	KRESCENT Curriculum Committee
2013 – 2014	Planning committee member, American Society of Nephrology 2014 ASN Kidney Week Conference

Journal Reviews:

New England Journal of Medicine
 JAMA
 Archives of Internal Medicine
 Circulation
 Journal of the American Society of Nephrology
 Nephrology Dialysis and Transplantation
 American Journal of Kidney Disease
 Kidney International
 Canadian Journal of Cardiology
 Clinical Journal of the American Society of Nephrology
 Canadian Medical Association Journal
 Canadian Journal of Cardiology

Editorial Board: Canadian Journal of Cardiology (2008 – 2011)
 Clinical Journal of the American Society of Nephrology (2010 – 2013;
 2014-2017)

Associate Editor: American Journal of Kidney Disease (July 1 2009 – Dec 31 2011)
 American Journal of Kidney Disease – second term (January 1 2012 – June 30,

2014)

Grant Review Committees

2015	Research Manitoba Team/Cluster Development Program
2011	International Society of Peritoneal Dialysis Grant Review Committee
2011 - 2015	CIHR – Population Health Research – Internal reviewer
2005 – 2009	Kidney Foundation of Canada Biomedical Scientific Review Cmttee Internal Reviewer for the Scientific Review Committee
2008 – 2009	CIHR Aboriginal Peoples' Health Committee Peer Review Committee – Internal reviewer
2004 – 2006	Heart and Stroke Foundation of Canada - External reviewer

Scholarship Review Committees

2007 - 2010	CIHR Canada Graduate Scholarships PhD Awards Committee
2007 - 2009	CIHR Canada Graduate Scholarship Master's Awards Committee
2009 - 2012	AHFMR Fellowship Training Committee

VIII. Research Support

1. *The transition to kidney allograft failure: characterizing risk and identifying opportunities for intervention*

<u>Principal Investigators:</u>	Ravani P
<u>Co-investigators:</u>	Quinn RR, Austin P, Campbell P, Knoll G, Hemmelgarn BR,
<u>Funding:</u>	\$567,204 (\$189,068/yr x 3 years)
<u>Funding sources:</u>	CIHR
<u>Years:</u>	2015 - 2018

2. *Systematic review of MID estimates and methods*

<u>Principal Investigators:</u>	Johnston BC, Guyatt GH, Nesrallah G
<u>Co-investigators:</u>	Hemmelgarn BR, and many
<u>Funding:</u>	\$100,000
<u>Funding sources:</u>	CIHR
<u>Years:</u>	2014 – 2015

3. *Improving the efficient and equitable care of patients with chronic medical conditions: the Interdisciplinary Chronic Disease Collaboration (ICDC)*

<u>Team Leaders:</u>	B Hemmelgarn, B Manns, M Tonelli
<u>Team members:</u>	many
<u>Funding:</u>	\$5,000,000
<u>Funding sources:</u>	Alberta Innovates-Health Solutions CRIO Team Grant
<u>Years:</u>	2014 – 2019

4. *Enhancing update of systematic reviews*

<u>Principal Investigators:</u>	S Straus, B Hemmelgarn
<u>Co-investigators:</u>	Hillmer M, Holroyd-Leduc J, Noseworthy T, Tonelli M et al
<u>Funding:</u>	\$305,382 total (3 years)
<u>Funding sources:</u>	CIHR

- Years: 2014-2017
- 5. *Cardiovascular risk among cancer survivors***
Principal Investigators: M Tonelli
Co-investigators: B Hemmelgarn, J Mackey, I Reiman, T Thompson
Funding: \$219,404 total (3 years)
Funding sources: CIHR
Years: 2014-2017
- 6. *Epidemiology, costs and consequences of multimorbidity***
Principal Investigators: M Tonelli
Co-investigators: T Braun, M Fortin, B Hemmelgarn, M James, S Klarenbach
Funding: \$275,700 total (3 years)
Funding sources: CIHR
Years: 2014-2017
- 7. *Implementation and evaluation of a clinical pathway for CKD in primary care***
Principal Investigators: B Hemmelgarn, T Braun, T Noseworthy, B Manns, M Tonelli
Co-investigators: K Jindal, M Jun, K King-Shier, A Levin, R Lewanczuk, C Naugler, P Sargious, N Scott-Douglas, S Straus
Funding: \$674,421 total (3 years)
Funding sources: CIHR
Years: 2013-2016
- 8. *An innovative service model for AHS and community-based pharmacist collaborative care of adult rural patients with chronic kidney disease***
Principal Investigators: R Tsuyuki, B Hemmelgarn
Co-investigators: M Tonelli, B Manns, K Jindal, N Scott-Douglas
Funding: \$800,291 total (2 years)
Funding sources: Alberta Health
Years: 2013-2015
- 9. *Emerging research and clinical priorities in the detection and management of frailty in older patients across acute care settings***
Principal Investigators: C Maxwell
Co-investigators: B Hemmelgarn, S Bagshaw, S Bronskill, D Hogan
Funding: \$25,000 total (1 year)
Funding sources: CIHR Planning Grant
Years: 2013
- 10. *The therapeutic evaluation of Steroids in IgA Nephropathy Global (TESTING) study – Canadian Network***
Principal Investigators: M Hladunewich, D Cattran, A Levin, H Reich
Co-investigators: B Hemmelgarn, S Barbour, W Clark, C Clase, N Pannu, M Sood, C Rigatto, S Soroka
Funding: \$884,666 total (6 years)

Funding sources: CIHR
Years: 2013-2019

11. *Effectiveness and cost of weekly rt-PA in hemodialysis patients at high risk for catheter complications: Quality assurance project of the implementation and evaluation of PreCLOT*

Principal Investigators: N Scott-Douglas, B Hemmelgarn
Co-investigators: A Levin, M Tonelli, B Richardson, M Sood, P Barre, S Soroka, D Mendelssohn, L Moist, C Lok, J MacRae B Manns
Funding: \$450,000 total (3 years)
Funding sources: Hoffman La-Roche
Years: 2013-2016

12. *The Canadian National Transplant Research Program: Increasing donation and improving transplant outcomes*

Principal Investigators: L West, T Calufield, MJ Hebert, A Humar, M Levings, S Mital, C Roy, K Schultz
Co-investigators: B Hemmelgarn and many others
Funding: \$11,250,000 total (5 years)
Funding sources: CIHR
Years: 2013-2018

13. *Identifying opportunities to improve care for patients after acute kidney injury*

Principal Investigators: N Pannu
Co-investigators: B Hemmelgarn, M James, S Klarenbach, M Tonelli
Funding: \$116,915 total (2 years)
Funding sources: CIHR
Years: 2013-2015

14. *Reducing the risk of serious adverse events and improving quality of life for patients with kidney disease: the role of AVF creation in hemodialysis patients*

Principal Investigators: R Quinn
Co-investigators: B Hemmelgarn, A Garg, S Hiremath, J MacRae, L Moist, M Oliver, P Ravani
Funding: \$230,846 total (2 years)
Funding sources: CIHR
Years: 2013-2015

15. *Do EMRs in primary care improve care and outcomes (EPIC)*

Principal Investigators: K Tu
Co-investigators: B Hemmelgarn, K Thorpe, J Narnsley, F Lau
Funding: \$100,000
Funding sources: CIHR
Years: 2013-2014

16. *Predicting the need for community care for chronic kidney disease following hospitalization with acute kidney injury*

Principal Investigators: M James
Co-investigators: B Hemmelgarn, P Austin, A Garg, B Manns, N Pannu, R Quinn, P Ravani, N Scott-Douglas, M Tonelli, R Wald
Funding: \$65,000/year for 2 years (130,000 total)
Funding sources: CIHR
Years: 2013-2015

17. *Quality of cancer care in remote-dwelling Canadians*

Principal Investigators: M Tonelli
Co-investigators: A Bello, J Dickinson, B Hemmelgarn, J Price Hiller, S Straus, N Wiebe, M Winget, H Yang
Funding: \$79,289/year for 3 years (\$237,868 total)
Funding sources: CIHR
Years: 2013-2016

18. *Methods of Assessing blood pressure: Identifying threshold and target values (MeasureBP)*

Principal Investigators: S Daskalopoulou, N Campbell, M Dawes, S Tobe
Team members: G Bartlett, B Hemmelgarn, N Khan, L Joseph, D McKay
Funding: \$97,872 over 1 year
Funding sources: CIHR Knowledge Synthesis Grant
Years: 2012

19. *Determining the research priorities of Canadian dialysis patients, caregivers and clinicians*

Principal Investigators: A Laupacis
Team members: B Hemmelgarn, B Manns, W Wolfs
Funding: \$25,000 over 1 years
Funding sources: CIHR Planning Grant
Years: Nov 2012 – Oct 2013

20. *Translating evidence to improvements in care and outcomes for people with diabetes*

Principal Investigators: B Manns, A Edwards, P Sargious
Team members: B Hemmelgarn, S Straus, J Grimshaw
Funding: \$24,995 over 1 years
Funding sources: CIHR Planning Grant
Years: 2012

21. *Arthritis in First Nations People in Alberta: Prevalence and Health Care Utilization*

Principal Investigators: B Hemmelgarn, C Barnabe
Team members: S Bernatsky, J Esdaile, L Joseph, C Peschken
Funding: \$150,250 over 2 years (\$75,125 per year)
Funding sources: CIHR Operating Grant
Years: 2011 – 2013

22. Innovative knowledge synthesis methods collaborative at the Li Ka Shing Knowledge Institute

Principal Investigators: S Straus, J Beyene
Team members: C Goldsmith, B Hemmelgarn, D Juurlink, S Majumdar
M Mamdani, L Perrier, A Tricco
Funding: \$950,000 over 3 years (\$316,666 per year)
Funding sources: CIHR Team Grant: DSEN Collaborating Ctre for
Meta-Analysis and innovative RCT Designs
Years: 2011 – 2014

23. The Canadian Kidney Knowledge Translation and Generation NETwork (CANN-NET)

Principal Investigators: B Manns, B Hemmelgarn, A Garg, S Klarenbach,
P Parfrey, S Samuel
Team members: M Evans, L MacCallum, F Madore, M Tonelli, R Ward,
M Walsh, M Zappitelli
Funding: \$600,000 over 3 years (\$200,000 per year)
Funding sources: CIHR Network Catalyst Grant
Years: 2011 – 2014

24. The impact of primary care networks on the care and outcome of patients with diabetes

Principal Investigator: B Manns, B Hemmelgarn, M Tonelli
Team members: F Clement, J Johnson, A Laupacis, K McBrien
Funding: \$256,226 over 2 years (\$128,113 per year)
Funding sources: CIHR
Years: 2011 – 2013

25. Canadian Network for Observational Drug Effect Studies (cNODES)

Principal Investigator: S Suissa, C Dormuth, D Henry, A Levy, P Martens,
R Platt
Team members: B Hemmelgarn, P Caetano, P Ernst, J LeLorier,
J Paterson, G Teare,
Funding: \$17,500,000 over 5 years (\$3,500,000 per year)
Funding sources: CIHR, Drug Safety Effectiveness Network (DSEN)
Years: 2011 – 2016

26. Improving risk prediction for mortality and progression to kidney failure in older adults using eGFR and proteinuria

Principal Investigator: B Hemmelgarn
Team members: F Clement, M James, B Manns, R Quinn, P Ravani,
M Tonelli
Funding: \$166,448 over 2 years (\$83,224 per year)
Funding sources: CIHR
Years: 2011 – 2013

27. Complications of arteriovenous fistulas, arteriovenous grafts and tunneled cuffed catheters for hemodialysis: Risk patterns, comparability and impact on patient outcomes

Principal Investigator: P Ravani
Team members: B Hemmelgarn, M James, B Manns, R Quinn, P Ravani,
Funding: \$130,000 over 2 years (\$65,000 per year)
Funding sources: CIHR
Years: 2011 – 2013

28. *The impact of reduced ICU bed availability due to the H1N1 pandemic on the care and outcomes of acutely unwell hospitalized patients*

Principal Investigator: H Stelfox, B Manns
Team members: B Hemmelgarn, C Doig, S Bagshaw
Funding: \$92,600 over 1 years
Funding sources: CIHR
Years: 2010 – 2011

29. *Predicting acute kidney injury (AKI) in patients undergoing cardiac surgery*

Principal Investigator: N Pannu
Team members: B Hemmelgarn, M Graham, M James, S Klarenbach
Funding: \$115,652 over 2 years
Funding sources: CIHR
Years: 2010 - 2012

30. *End stage renal disease in Canadian Aboriginal Children*

Principal Investigator: S Koshy
Team members: B Hemmelgarn, M Tonelli, B Foster
Funding: \$49,556
Funding sources: Alberta Children's Hospital Foundation
Years: 2010

31. *Assessment of hypertension occurrence, management and outcomes in Canada*

Co-Principal Investigators: H Quan, B Hemmelgarn, K Tu
Team members: McAlister F, Campbell N, Svenson L, Lix L, Teare G,
 Wielgosz A, Smith M, Khan N, Hill M, Bartlett-Esquilant G
Funding: \$570,217 for 3 years
Funding sources: CIHR
Years: 2009 - 2012

32. *Assessment of hypertension occurrence, management and outcomes in Canada*

Co-Principal Investigators: H Quan, B Hemmelgarn, K Tu
Team members:
Funding: \$100,000
Funding sources: CIHR
Years: 2008 – 2009

33. *Effects of physician alternative payments plans on the completeness and validity of administrative health data*

Co-Principal Investigators: H Quan, N Jette
Team members: S Koshy, E Dixon, C Beck, W Ghali
Funding: \$205,217 for 2 years
Funding sources: CIHR
Years: 2009 - 2011

34. *Enhancing existing capacity in applied health services and policy research in Western Canada*

Team Leaders: B Sheps, A Backman, L Barer, A Casebeer, M Doupe, K Kelly, L Lix, G Marchildon, P Martens, H Quan
Team members: (many) B Hememlgarn
Funding: \$298,333 / year for 6 years
Funding sources: CIHR Training Program Grant
Years: 2009 - 2015

35. *Improving the efficient and equitable care of patients with chronic medical conditions: the Interdisciplinary Chronic Disease Collaboration (ICDC)*

Team Leaders: B Hemmelgarn, B Manns, M Tonelli
Team members: many
Funding: \$5,004,920
Funding sources: AHFMR Interdisciplinary Team Grant
Years: 2009 – 2014

36. *Assessment of survey sampling methodologies for studying hard to reach population: Minority Francophones in Calgary*

Principal investigator: H Quan, K King
Co-Investigators: B Hemmelgarn, E Ngwakongnwi, R Musto,
Funding: \$50,000/year x 1 years
Funding sources: CIHR
Years: 2009 - 2010

37. *Access to and quality of cardiac care for First Nations*

Principal investigator: B Hemmelgarn
Co-Investigators: S Ahmed, W Ghali, M Knudtson, M Tonelli, B Manns, P Faris, H Quan.
Funding: \$215,875 over 3 years
Funding sources: CIHR
Years: 2009 – 2012

38. *Longitudinal comparison of quality of life among kidney transplant recipients and nocturnal home hemodialysis patients*

Principal investigator: R Pauly
Co-Investigators: B Hemmelgarn, J MacRae, J Gill, S Klarenbach, M Copland, M Tonelli, Gourishankar, J Chan
Funding: \$136,000 over 3 years
Funding sources: CIHR

Years: 2009 – 2012

39. Genetic markers of risk in hemodialysis patients

Principal investigator: M Tonelli
Co-Investigators: B Hemmelgarn, J Gill, J Chan et al.
Funding: \$3,659,002 over 5 years
Funding sources: CIHR Industry Partnered Program (with Abbott Labs)
Years: 2008 - 2012

40. Health outcomes during transition to adulthood in pediatric patients with ESRD

Principal investigator: S Koshy
Co-Investigators: B Hemmelgarn, M Tonelli
Funding: \$46,112
Funding sources: Alberta Children's Hospital Foundation
Years: 2008 – 2009

41. Contrast induced nephropathy and progression of kidney disease after coronary angiography

Principal investigator: B Hemmelgarn
Co-Investigators: M James, W Ghali, M Knudtson
Funding: \$48,295/year x 1 years
Funding sources: Kidney Foundation of Canada
Years: 2008 - 2009

42. Health service utilization: Survey of less English proficient Francophones in Calgary Health Region

Principal investigator: H Quan, K King
Co-Investigators: B Hemmelgarn, E Ngwakongnwi, N Khan, R Musto,
Funding: \$50,000/year x 1 years
Funding sources: CIHR
Years: 2008 - 2009

43. Validation of a coding algorithm to define chronic kidney disease using administrative data

Principal investigator: B Hemmelgarn
Co-Investigators: H Quan, B Manns, M Tonelli
Funding: \$96,725/year x 1 years
Funding sources: Public Health Agency of Canada
Years: 2008 - 2009

44. Progression and management of chronic kidney disease among First Nations People

Principal investigator: B Hemmelgarn
Co-Investigators: S Ahmed, L Crowshoe, P Faris, W Ghali, B Manns, M Tonelli
Funding: \$79,421/year x 2 years
Funding sources: CIHR
Years: 2008 - 2010

45. *Role of residence location in the care of elderly Canadians with kidney failure*

Principal investigator: M Tonelli
Co-Investigators: S Davison, J Gill, B Hemmelgarn, S Klarenbach, B Manns, N Pannu, N Wiebe, K Yeates
Funding: \$130,476/year x 5 years
Funding sources: CIHR
Years: 2008 - 2013

46. *Access to health research: Participation and empowerment of Aboriginal Peoples in research to improve health and well-being((APH-NEAHR Proposal)*

Principal investigator: M King
Co-Investigators: L Crowshoe, L Clearsky, C Voyageur, B Hemmelgarn
Funding: \$1,749,999
Funding sources: CIHR
Years: 2007 – 2011

47. *Influence of deficiency and excess of trace elements on outcomes in hemodialysis patients*

Principal investigator: M Tonelli
Co-Investigators: B Hemmelgarn, G Cembrowski, B Culleton, C Field, J Gill, K Jindal, S Klarenbach, B Manns, N Wiebe
Funding: \$996,000
Funding sources: CIHR
Years: 2007 - 2012

48. *Type 2 Diabetes in Aboriginal peoples in Alberta: validation of incidence, prevalence, complications and health care utilization.*

Principal investigator: E Toth
Co-Investigators: B Hemmelgarn,
Funding: \$149,972
Funding sources: CIHR
Years: 2007 – 2009

49. *Validation of a coding algorithm to define hypertension using administrative data*

Principal investigator: H Quan
Co-Investigators: B Hemmelgarn, K Tu, N Khan, N Campbell, W Ghali, F McAlister, M Hill
Funding: \$125,530
Funding sources: CIHR
Years: 2006 - 2008

50. *Modeling chronic kidney disease: Optimal modeling methods and implications for screening programs for chronic kidney disease*

Principal investigator: S Klarenbach, BJ Manns
Co-Investigators: B Hemmelgarn, N Scott-Douglas, K Jindal, B Culleton, S Gao

<u>Funding:</u>	\$100,000
<u>Funding sources:</u>	AHFMR
<u>Years:</u>	2006 – 2008

51. *Impact of GFR reporting on management of chronic kidney disease and health care utilization*

<u>Principal investigator:</u>	B Hemmelgarn
<u>Co-Investigators:</u>	L Thorlacius, R Krause, N Scott-Douglas, K Jindal
<u>Funding:</u>	\$100,000
<u>Funding sources:</u>	Kidney Foundation of Canada
<u>Years:</u>	2006 – 2008

52. *Chronic kidney disease among First Nations people in Alberta: Prevalence, progression and access to care*

<u>Principal investigator:</u>	B Hemmelgarn
<u>Co-Investigators:</u>	B Manns, B Culleton, M Tonelli, L Crowshoe, L Svenson, WA Ghali, S Bertazzon,
<u>Funding:</u>	\$210,000
<u>Funding sources:</u>	CIHR
<u>Years:</u>	2005 - 2008

53. *The role of place and relocation in the care of Canadians with end-stage renal disease*

<u>Principal investigator:</u>	M Tonelli
<u>Co-Investigators:</u>	B Manns, B Culleton, B Hemmelgarn, J Gill,
<u>Funding:</u>	\$180,000
<u>Funding sources:</u>	CIHR
<u>Years:</u>	2005 – 2008

54. *Evaluating the impact of a restricted reimbursement policy for selected antimicrobial agents on utilization of targeted antibiotics, clinical outcomes, and costs*

<u>Principal investigator:</u>	B Manns
<u>Co-Investigators:</u>	B Hemmelgarn, K Laupland, C Mitchell
<u>Funding:</u>	\$47,000
<u>Funding sources:</u>	Institute of Health Economics
<u>Years:</u>	2005 – 2007

55. *Image analysis of interstitial injury in kidney biopsies as a prognostic marker in IgA nephropathy*

<u>Principal investigator:</u>	B Hemmelgarn / M Walsh (nephrology fellow)
<u>Co-Investigators:</u>	B Manns, H Benedictson, S Yilmaz
<u>Funding:</u>	\$7,900
<u>Funding sources:</u>	Calgary Laboratory Services
<u>Years:</u>	2005 - 2006

56. *Prevention of Catheter Lumen Occlusion with rTPA versus Heparin (Pre-CLOT): A Double Blind Randomized Trial*

Principal investigator: N Scott-Douglas
Co-Principal Investigator: B Hemmelgarn
Funding: \$1,340,945
Funding sources: Hoffman La-Roche
Years: 2004 - 2009

57. Chronic kidney disease among First Nations in Alberta: A research agenda

Principal investigator: B Hemmelgarn
Co-investigators: B Manns, B Culleton, M Tonelli, K McLaughlin
Funding: \$25,000
Funding sources: Petro-Canada Young Innovator Award
Years: 2004 – 2005

58. Chronic kidney disease among elderly in southern Alberta

Principal investigator: B Hemmelgarn
Co-investigators: B Manns, B Culleton, M Tonelli, K McLaughlin
Funding: \$4,800
Funding sources: Centre for Advancement of Health, U of C
Years: 2004 – 2005

59. Chronic kidney disease among the elderly in Alberta: Prevalence and access to care

Principal investigator: B Hemmelgarn
Co-investigators: B Manns, B Culleton, M Tonelli, S Bertazzon
 K Taub, M Visser
Funding: \$98,572
Funding sources: AHFMR
Years: 2004 - 2006

60. A computerized chronic kidney disease network: A database for accessing care and determining progression

Proposal author: K Taub, B Manns, B Culleton, B Hemmelgarn
Principal investigator: K Taub
Co-Principal Investigators: B Manns, B Culleton, B Hemmelgarn, K McLaughlin
Funding: \$480,000 total (\$120,000 / yr)
Funding sources: Amgen Canada
Years: 2004 - 2008

61. A prospective evaluation of kidney function in a community-based elderly population.

Proposal author: BR Hemmelgarn *
Principal investigator: B Culleton *
Co-investigators: K McLaughlin, G Mortis, W Ghali, E Larsen
Funding: \$92,160.00
Funding sources: Kidney Foundation of Canada
Years: 2002 - 2004

62. Chronic kidney disease among First Nations in Southern Alberta.

Proposal author: B Hemmelgarn

Principal investigator: B Hemmelgarn
Co-investigators: B Manns, B Culleton, M Tonelli, K McLaughlin
Funding: \$8,837 total
Funding sources: University of Calgary
Years: 2004

63. *Fish Oil inhibition of stenosis in hemodialysis grafts.*

Proposal author: C Lok
Principal investigator: C Lok
Co-investigators: B Hemmelgarn, M Tonelli, L Moist, M Oliver
Funding: \$319,134 total
Funding sources: CIHR
Years: 2004 – 2007

64. *Optimizing prevention of vascular disease in Alberta: A program of health outcomes research.*

Proposal author: F McAlister
Principal investigator: F McAlister
Co-investigators: B Hemmelgarn, B Manns, B Culleton M Tonelli
Funding: \$210,000 total
Funding sources: AHFMR
Years: 2004 – 2007

65. *Electronic decision support for improving the care of hemodialysis patients in Alberta*

Proposal author: M Tonelli
Principal investigator: M Tonelli
Co-investigators: B Hemmelgarn, K McLaughlin, G Mortis
Funding: \$149,968
Funding sources: AHFMR
Years: 2004 – 2006

66. *Benzodiazepine use and the risk of motor vehicle crashes in the elderly*

Proposal author: BR Hemmelgarn *
Principal investigator: S Suissa *
Co-investigators: P Ernst, JF Boivin
Funding: \$136,180.00
Funding sources: National Health Research and Development Program (NHRDP)
Years: 1993 – 1996

67. *Asthma in Inuit children: Prevalence and determinants*

Proposal author: P Ernst
Principal investigator: P Ernst
Co-investigators: BR Hemmelgarn, J Hanley, P Comtois, G Julien, Y Cormier
Funding: \$396,425.00
Funding sources: National Health Research and Development Program

(NHRDP)
1993 – 1996

Years:

* With the assistance of the principal investigator, Dr Hemmelgarn developed and wrote the grant proposals but was not listed as principal investigator as granting agencies require principal investigators to have a faculty appointment.

IX. Invited Addresses

1. Joint initiative on Health Science Programs for native students. Eighth International Congress on Circumpolar Health, Whitehorse, Yukon. May 1990.
2. National Native Access Program to Nursing: Learning from the experience. Northern Nurses Conference, Whitehorse, Yukon. 1990.
3. The relationship between specified factors and role strain in employed mothers. Nursing Conference - Women's Health Issues, Winnipeg, Manitoba. September 1990.
4. Incidence of respiratory and gastrointestinal disease among native children in Northern Saskatchewan. Respiratory Epidemiology Seminar Series, McGill University, Montreal, Quebec. October 1991.
5. Identifying the health information needs of mothers and infants. Saskatchewan Public Health Nurses Continuing Education Conference. University of Saskatchewan, Saskatoon. 1991.
6. Evaluation of child health clinics in Saskatoon. Department of Community Health & Epidemiology Seminar Series. University of Saskatchewan, Saskatoon. 1991.
7. Airways hyperresponsiveness and atopy in Inuit schoolchildren. European Respiratory Conference, Nice, France. October 1994.
8. Theophylline and β -agonist use: the risk of cardiovascular death in asthma. 11th International Conference on Pharmacoepidemiology, Montreal, Canada. August 1995.
9. A case study of hospital closure and centralization of coronary revascularization procedures. Residents Research Day. University of Calgary, Alberta. May 2001.
10. Metabolic complications of chronic kidney disease. Alberta Nephrology Days. Edmonton, Alberta. May 2004.
11. Assessment of kidney function: The importance of creatinine standardization. Alberta Society of Clinical Chemists. Calgary, Alberta. May 2004.
12. Progression of chronic kidney disease in a community-based elderly population. American Society of Nephrology Annual Meeting, St Louis MI. October 2004.
13. Assessment and management of diabetic nephropathy. First Nations and Inuit Health Branch Nursing Inservice. Teleconference to locations throughout Alberta. December 7 2004.
14. Assessment and management of chronic kidney disease. Nurse Practitioner Course. University of Calgary, Alberta. February 10 2005.
15. Acute dialysis in the emergency room. Patient management and the dialysis prescription. Southern Alberta Renal Program Nursing Conference. February 27, 2005.
16. Progression of chronic kidney disease: Is there really an epidemic? Alberta Nephrology Days, Banff AB. April 29 2005.
17. Chronic kidney disease and cardiovascular disease – is there really an association? TORCH lecture. Calgary / Edmonton (teleconference) May 12, 2005.
18. Ethical misfortune: What could have been done differently. TORCH Workshop: Ethics in Research. Edmonton September 29, 2005.

19. Diabetic kidney disease. Julia McFarlane Diabetes Research Centre Third Annual Diabetes Awareness Day. Calgary November 26 2005.
20. Kidney Research in Alberta. Kidney foundation of Canada Keynote Address. Calgary, May 2006.
21. Cardiac intervention advances in PD patients. 11th International Congress of the International Society for Peritoneal Dialysis. Hong Kong, August 2006.
22. End-stage renal disease among Aboriginal people. CSCI Joe Doupe Lecture. Ottawa, ON. September 2006.
23. Chronic kidney disease in the elderly. Brooks Diabetes Education Day, Key-note speaker. Brooks AB. February 2007.
24. Use of laboratory data for clinical research in kidney disease. Nephrology Rounds, University of Toronto. March 2007.
25. Renal disease and vascular risk. 2nd Annual Vascular Biology Conference. University of Calgary, Calgary AB. April 2007.
26. Clinical research in kidney disease in Alberta: A profile. Kidney Foundation of Canada. Lethbridge AB. May 2007.
27. Canadian Society of Nephrology State of the Art Lecture: Clinical research in kidney disease using laboratory data. Halifax Nova Scotia. May 2007.
28. Progression and management of chronic kidney disease in the elderly. German Society of Nephrology. Munich Germany, September 2007.
29. Clinical research in the Southern Alberta Renal Program. Nurse Educators Forum. Calgary, February 2008.
30. Natural history of chronic kidney disease in the elderly. National Kidney Foundation meeting. Dallas Texas, April 2008.
31. ACE and/or ARB in the management of hypertension among high risk groups. Alberta Nephrology Days, Jasper, Alberta, April 2008.
32. Treatments to retard progression of chronic kidney disease and management of the disease in older adults. American Society of Nephrology. Washington, DC. May 2008.
33. Kidney disease among Aboriginal People: Development of an outreach clinic. Nurse Educators Forum, Calgary, June 2008.
34. Approach to hypertension. TORCH. Calgary, November 2008.
35. Kidney Disease among First Nations People. Assembly of First Nations, Special Chiefs Assembly. Ottawa, December 2008.
36. The Alberta Kidney Disease Network: An overview. Horizons 2015. Kidney Foundation of Canada. Montreal, March 2009.
37. Internal Medicine Residents Retreat – Key note speaker. The importance of mentoring. Kananaskis AB, March 2009.
38. North American Chapter Meeting of the International Society for Peritoneal Dialysis. ESRD and Diabetes among First Nations People. Vancouver BC, August 2009.
39. KDIGO CKD Consensus Conference. CKD and pneumonia. London, England. October 2009
40. Grand Rounds – Cardiology. University of Calgary. The heart-kidney connection. January 2010, Calgary, Alberta.
41. University of Manitoba Nephrology Grand Rounds. Kidney disease among Aboriginal people. April 2010, Winnipeg, Manitoba.
42. 54th Conference of the Canadian Society of Clinical Chemists. Diabetes and kidney disease among the Aboriginal population. June 2010. Saskatoon, Saskatchewan.

43. Grand Rounds – Nephrology. University of British Columbia. Kidney disease among different ethnic groups. Nov 2010, Vancouver BC.
44. American Society of Nephrology. Prevention of catheter lumen occlusion with rt-PA versus heparin: A randomized trial (PreCLOT). Denver, Colorado. November 2010
45. Nephrology Educators' Forum. Using computerized data for health services research. Montreal, Quebec. February 2011.
46. Sunnybrook Nephrology Rounds. Kidney disease among Aboriginal People. Sunnybrook Health Sciences Centre, Toronto, ON. February 2011.
47. Modes of health care delivery for CKD: Prevention / disease management programs. World Congress of Nephrology, Vancouver BC. April 17 2011.
48. Peritoneal dialysis use among Aboriginal People. PD University, Calgary, AB, May 7 2011.
49. Use of computerized data for health services research in kidney disease. Uldall Annual Dinner, Toronto, Invited Keynote Speaker, Toronto ON. June 1 2011.
50. Central venous catheters: Strategies for prevention of malfunction and infection. Uldall Annual Dinner, Toronto, Invited Keynote Speaker, Toronto ON. June 1 2011.
51. Kidney disease among Aboriginals: Strategies for improvement. Dept of Medicine Grand Rounds, University of Calgary, June 7 2011.
52. IF series. Calgary Chamber of Commerce invited speaker. Calgary, June 22, 2011.
53. Use of administrative and lab data for health services research. CCHCSP Conference Ottawa, ON, Oct 15 2011.
54. Strategies for prevention of malfunction and infection with central venous catheters. Canadian Association of Nephrology Nurses Conference. Calgary, AB, Oct 21, 2011.
55. Role of albuminuria/proteinuria in the diagnosis and prognosis of CKD in older adults. American Society of Nephrology Invited Lecture, Philadelphia, PA, Nov 8 2011.
56. The prognostic implications of proteinuria in CKD. American Society of Nephrology Invited Lecture, Philadelphia, PA, Nov 10 2011.
57. Does eGFR reporting improve the care of people with CKD? American Society of Nephrology Invited Lecture, Philadelphia, PA, Nov 11 2011.
58. Use of computerized data for health services research: The Alberta Kidney Disease Network. Division of Nephrology Rounds, Ottawa, ON, Nov 29 2011.
59. Central venous catheters: Strategies for prevention of malfunction and infection. Fellows Seminar, Division of Nephrology, Ottawa, ON, Nov 29 2011.
60. Nephrology referral and outcomes for Aboriginal People with ESRD. Canadian Society of Nephrology Annual General Meeting, St Johns Nfld April 29 2012.
61. Assessment of kidney function and practical applications. Canadian Stroke Congress, Calgary AB October 1, 2012.
62. Hypertension and chronic kidney disease: Special considerations. Hypertension Canada Annual Meeting, Toronto, Oct 25 2012.
63. Update on the CKD and hypertension guidelines. SARP Education Day, Calgary, March 15 2013.
64. What's new in the KDIGO CKD guidelines? National Kidney Foundation annual meeting, Orlando Florida, April 4, 2013.
65. Proteinuria and its impact in the elderly. National Kidney Foundation annual meeting, Orlando Florida, April 5, 2013.
66. Clinical practice guidelines and the care of older adults with CKD. Kidney Week 2012, American Society of Nephrology Annual Meeting. Atlanta GA. November 5 2013.

67. Care of patients with chronic kidney disease in the community. University of Calgary Family Practice Review and Update Course. Calgary, AB. November 18, 2013.
68. What are the research priorities of patients with end-stage renal disease? CIHR INMD young investigators meeting, Banff, AB Jan 17 2014.
69. Use of a CKD Clinical Pathway in Primary care. Rural physicians of Alberta video-conference. Oct 7, 2014.
70. Patient engagement in setting research priorities. BC Kidney Days Vancouver BC, Oct 16, 2014.
71. Chronic kidney disease clinical pathway. 39th Annual Pearls for Practice – Family Practice Review and Update Course. Calgary, AB, Nov 17 2014.
72. From efficacy to effectiveness to implementation. KDIGO Consensus Conference. Vancouver, BC Feb 6 2015.
73. Use of the CKD Clinical Pathway in clinical practice. Family Medicine Resident Academic Session. Calgary, Feb 19 2015.
74. An online CKD Clinical Pathway in primary care: What it can do for you. Calgary West Central Primary Care Network. Calgary, April 1 2015.
75. Enhancing management of CKD in the community. Canadian Association of Nephrology Administrators Annual Meeting. Montreal, April 23 2015.
76. An online CKD Clinical Pathway in primary care: What it can do for you. Calgary MOSAIC Primary Care Network. Calgary, May 28 2015.

X. Publications

i. Peer Reviewed Manuscripts:

Underline indicates trainee for whom I provided research supervision.

Years 1991 - 2006

1. **Hemmelgarn BR**, Laing G. The relationship between identified factors and perceived role strain in employed mothers. *Family and Comm Health* 1991;14(1):8-15.
2. **Hemmelgarn BR**. Increasing response rates in community health surveys. *Can J Public Health* 1991;82(5):353-354.
3. Horwitz R, Spitzer W, Buist S, Cockcroft D, Ernst P, Habbick B, **Hemmelgarn BR**, McNutt M, Rebuck A, Suissa S. Clinical complexity and epidemiologic uncertainty in case-control research: Fenoterol and asthma management. *Chest* 1991;100(6):1586-1591.
4. **Hemmelgarn BR**, Edouard L, Habbick B, Feather J. Duplication of well-baby services. *Can J Public Health* 1992;83(3):217-220.
5. **Hemmelgarn BR**, Klassen R, Habbick B, Senthilselvan A. Use of gastrointestinal and respiratory illness hospitalization rates as indicators of different social influences. *Can J Public Health* 1993;84(2):136-138.
6. Suissa S, **Hemmelgarn BR**, Spitzer WO, Brophy J, Collet JP, Cote R, Downey W, Edouard L, Leclerc J, Paltiel O. The Saskatchewan oral contraceptive cohort study of oral contraceptive use and cardiovascular risks. *Pharmacoepidemiology & Drug Safety* 1993;2(1):33-49.
7. Ernst P, Habbick B, Suissa S, **Hemmelgarn BR**, Cockcroft D, Buist AS, Horwitz RI, McNutt M, Spitzer WO. Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity? *Am Rev Respir Dis* 1993;148:75-79.
8. **Hemmelgarn BR**, Blais L, Collet JP, Ernst P, Suissa S. Automated databases and the need for fieldwork in pharmacoepidemiology. *Pharmacoepidemiology & Drug Safety* 1994;3:275-282.

9. Ernst P, **Hemmelgarn BR**, Cockcroft DW, Suissa S. Over-reliance on bronchodilators as a risk factor for life threatening asthma. *Can Respir J* 1995;2(1):34-39.
10. **Hemmelgarn BR**, Loozen E, Saralegui S, Chatwood S, Ernst P. Airway hyperresponsiveness and atopy: a comparison of Inuit and Montreal schoolchildren. *Can Respir J* 1995;2(2):92-96.
11. Suissa S, **Hemmelgarn BR**, Blais L, Ernst P. Bronchodilators and acute cardiac death. *Am J Respir Crit Care Med* 1996;154:1598-1602.
12. **Hemmelgarn BR**, Suissa S, Huang A, Boivin JF, Pinard G. Benzodiazepine use and the risk of motor vehicle crash in the elderly. *JAMA* 1997;278(1):27-31.
13. **Hemmelgarn BR**, Ernst P. Airway function among Inuit primary school children in far northern Quebec. *Am J Respir Crit Care Med* 1997;156:1870-1875.
14. Panju AA, **Hemmelgarn BR**, Guyatt GH, Simel DL. Is this patient having a myocardial infarction? *JAMA* 1998;280:1256-1263.
15. **Hemmelgarn BR**, Ghali WA, Quan H, Brant R, Norris CM, Taub KJ, Knudtson ML. Poor long-term survival after coronary angiography in patients with renal insufficiency. *Am J Kidney Dis* 2001;37:64-72.
16. **Hemmelgarn BR**, Ghali WA, Quan H. A case study of hospital closure and centralization of coronary revascularization procedures. *CMAJ* 2001;164:1431-1435.
17. **Hemmelgarn BR**, Manns BJ, Quan H, Ghali WA. Adapting the Charlson Comorbidity Index for use in patients with ESRD. *Am J Kidney Dis* 2003;42:125-132.
18. **Hemmelgarn BR**, Zarnke K, Campbell NRC, Feldman RD, McKay DW, McAlister FA, Knah N, Schiffrin EL, Myers MG, Bolli P, Honos G, Lebel M, Levine M. The 2003 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: Part 1. Blood pressure measurement, diagnosis, and assessment of risk. *Can J Cardiol* 2004;20:31-40.
19. Khan NA, McAlister FA, Campbell NRC, Feldman RD, Mahon J, Lewanczuk R, Rabkin SW, Zarnke K, **Hemmelgarn BR**, Lebel M, Levine M, Herbert C, Touyz R. The 2003 Canadian Hypertension Recommendations for the management of hypertension: Part 2. Therapy. *Can J Cardiol* 2004;20:41-54.
20. Etiman M, **Hemmelgarn BR**, Delaney JAC, Suissa S. Lithium use and the risk of injurious motor vehicle crash in older adults. *BMJ* Jan 2004 328:558-559.
21. Tonelli M, **Hemmelgarn BR**, Manns B, Pylypchuk G, Bohm C, Yeates K, Gourishanker S, Gill JS. Death and renal transplantation among Aboriginal people undergoing dialysis. *CMAJ* 2004;171:577-582.
22. **Hemmelgarn BR**, Southern D, Culleton BF, Mitchell LB, Knudtson ML, Ghali WA. Survival following coronary revascularization among patients with kidney disease. *Circulation* 2004;110:1890-1895.
23. Tonelli M, **Hemmelgarn BR**, Manns B, Davison S, Bohm C, Gourishankar S, Pylypchuk G, Yeates K, Gill JS. Use and outcomes of peritoneal dialysis among Aboriginal people in Canada. *J Am Soc Nephrol* 2005;16:482-488.
24. **Hemmelgarn BR**, McAlister FA, Myers MG, McKay DW, Bolli P, Abbott C, Schiffrin EL, Grover S, Honos G, Lebel M, Mann K, Wilson T, Penner B, Tremblay G, Tobe SW, Feldman RD. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I – Blood pressure measurement, diagnosis, and assessment of risk. *Can J Cardiol* 2005;21:645-656.
25. Myers MG, Tobe SW, McKay DW, Bolli P, **Hemmelgarn BR**, McAlister FA. New algorithm for the diagnosis of hypertension. *Am J Hypertens* 2005;18:1369-1379.

26. **Hemmelgarn BR**, Grover S, Feldman RD. Applying the 2005 Canadian Hypertension Education Program Recommendations. Global atherosclerotic risk in hypertensive patients: Assessment and strategies to reduce risk. *CMAJ* 2005;173:593-595.
27. Khan NA, **Hemmelgarn BR**, Tonelli M, Thompson CR, Levin A. Prognostic value of Troponin T and I among asymptomatic patients with end stage renal disease: A meta-analysis. *Circulation* 2005;112:3088-3096.
28. Tonelli M, Chou SH, Gourishankar S, Jhangri GS, Bradley J, **Hemmelgarn BR**. Wait-listing for renal transplantation among Aboriginal hemodialysis patients. *Am J Kidney Dis* 2005;46:1117-1123.
29. Chou SH, Tonelli M, Bradley JS, Gourishankar S, **Hemmelgarn BR**. Quality of care among Aboriginal hemodialysis patients. *Clin J Am Soc Nephrol* 2006;1:58-63.
30. **Hemmelgarn BR**, Zhang J, Manns BJ, Tonelli M, Larsen E, Ghali WA, Southern DA, McLaughlin K, Mortis G, Culleton BF. Progression of kidney dysfunction in the community-dwelling elderly. *Kidney Int* 2006;69:2155-2161.
31. Culleton BF, Manns BJ, Zhang J, Tonelli M, Klarenbach S, **Hemmelgarn BR**. Impact of anemia on hospitalization and mortality in older adults. *Blood* 2006; 107:3841-3846.
32. **Hemmelgarn BR**, Moist L, Pilkey RM, Lok C, Dorval M, Tam PYW, Berall MJ, LeBlanc M, Toffelmire EB, Manns BJ, Scott-Douglas N. Prevention of catheter lumen occlusion with rT-PA versus heparin (PreCLOT): Study protocol of a double blind randomized trial. *BMC Nephrology* 2006;7:8 (11 Apr 2006).
33. **Hemmelgarn BR**, Levesque LE, Suissa S. Anti-diabetic drug use and the risk of motor vehicle crash in the elderly. *Can J Clin Pharmacol* 2006;13:e112-20.
34. **Hemmelgarn BR**, Southern D, Humphries KH, Culleton BF, Knudtson ML, Ghali WA. Refined characterization of the association between kidney function and mortality in patients with cardiovascular disease. *Eur Heart J* 2006;27:1191-1197.
35. Moist L, **Hemmelgarn BR**, Lok CE. Relationship between blood flow in central venous catheters and hemodialysis adequacy. *Clin J Am Soc Nephrol* 2006;1:965-971.
36. **Hemmelgarn BR**, McAlister FA, Grover S, Myers MG, McKay DW, Bolli P, Abbott C, Schiffrin EL, Honos G, Burgess E, Mann K, Wilson T, Penner B, Tremblay G, Milot A, Chockalingam A, Touyz RM, Tobe SW. The 2006 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: Part I – Blood pressure measurement, diagnosis, and assessment of risk. *Can J Cardiol* 2006;22:573-581.
37. Khan NA, McAlister FA, Rabkin SW, Padwal R, Feldman RD, Campbell NR, Letier LA, Lewanczuk RZ, Schiffrin EL, Hill MD, Arnold M, Moe G, Campbell TS, Herbert C, Milot A, Stone JA, Burgess E, **Hemmelgarn BR**, Jones C, Larochelle P, Ogilvie RI, Houlden R, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, Dechamplain J, Pylypchuk G, Logan AG, Gledhill N, Petrella R, Tobe S, Touyz RM. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II – Therapy. *Can J Cardiol* 2006;22:583-593.
38. Grover SA, **Hemmelgarn BR**, Joseph L, Milot A, Tremblay G. The role of global risk assessment in hypertension therapy. *Can J Cardiol* 2006;22:606-613.
39. Tonelli M, **Hemmelgarn BR**, Kim AKJ, Bertazzon S, Klarenbach S, Manns B, Wiebe N, Culleton B, Gill JS. Association between residence location and likelihood of kidney transplantation in Aboriginal patients treated with dialysis in Canada. *Kidney Int* 2006;70:924-930.

40. Tonelli M, Klarenbach S, Manns B, Culleton B, **Hemmelgarn BR**, Bertazzon S, Wiebe N, Gill JS. Association between residence location and likelihood of kidney transplant. *CMAJ* 2006;175:478-482.
41. **Hemmelgarn BR**, Chou S, Wiebe N, Culleton BF, Manns BJ, Klarenbach S, Khan NA, Gourishankar S, Yeates KE, Gill JS, Tonelli M. Differences in use of peritoneal dialysis and survival among East Asian, Indo Asian and White end-stage renal disease patients in Canada. *Am J Kidney Dis* 2006;48:964-971.

Year 2007

42. **Hemmelgarn BR**, Manns BJ, Zhang J, Tonelli M, Klarenbach S, Walsh M, Culleton BF. Association between multidisciplinary care and survival for elderly patients with chronic kidney disease. *J Am Soc Nephrol* 2007;18:993-999.
43. Gooch K, Culleton BF, Manns BJ, Tonelli M, Klarenbach S, Zhang J, **Hemmelgarn BR**. Non-steroidal anti-inflammatory drug use in the elderly and risk for progression of chronic kidney disease. *Am J Medicine* 2007;120:e1-7.
44. Hebert C, Delaney JAC, **Hemmelgarn BR**, Levesque LE, Suissa S. Benzodiazepines and older drivers: A comparison of pharmacoepidemiological study designs. *Pharmacoepidemiology and Drug Safety* 2007;16:1-5.
45. **Hemmelgarn BR**, Culleton BF, Ghali WA. Derivation and validation of a clinical index for prediction of rapid progression of kidney dysfunction. *Q J Med* 2007;100:87-92.
46. Padwal RS, **Hemmelgarn BR**, McAlister F, et al. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of risk. *Can J Cardiol* 2007;23:529-538.
47. Khan NA, **Hemmelgarn BR**, Padwal R, et al. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy. *Can J Cardiol* 2007;23:539-550.
48. Bolli P, **Hemmelgarn BR**, Myers MG, McKay D, Tremblay G, Tobe SW. High normal blood pressure and prehypertension: The debate continues. *Can J Cardiol* 2007; 23:581-583.
49. Tonelli M, **Hemmelgarn BR**, Gill JS, Chou S, Culleton BF, Manns B, Klarenbach S, Wiebe N, Gourishankar S. Patient and allograft survival among Indo and East Asian dialysis patients treated in Canada. *Kidney Int* 2007;72:499-504.
50. Thomas CM, Zhang J, Lim TH, Scott-Douglas N, Hons RB, **Hemmelgarn BR**. Concentration of heparin locking solution and risk of central venous hemodialysis catheter malfunction. *ASAIO Journal* 2007;53:485-488.
51. Walsh M, James M, Jayne D, Tonelli M, Manns BJ, **Hemmelgarn BR**. Mycophenolate mofetil for induction therapy of lupus nephritis: A systematic review and meta-analysis. *Clin J Am Soc Nephrol* 2007;2:968-975.
52. Lok CE, Allon M, Donnelly S, Dorval M, **Hemmelgarn BR**, Moist L, Oliver MJ, Tonelli M, Stanley K. Design of the fish oil inhibition of stenosis in hemodialysis (FISH) study. *Clinical Trials* 2007;4:357-367.
53. Jassal SV, Trpeski L, Badovinac K, Fenton SSA, **Hemmelgarn BR**. Changes in survival among elderly patients initiating dialysis from 1990 to 1999. *CMAJ* 2007;177:1033-1038.
54. Gao S, Manns BJ, Culleton BF, Tonelli M, Quan H, Crowshoe L, Ghali WA, Svenson LW, **Hemmelgarn BR**. Prevalence of chronic kidney disease and survival among Aboriginal People. *J Am Soc Nephrol* 2007;18:2953-2959.

55. Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, Quinn R, Tonelli M, Donnelly S, Friedrich MG, Kumar A, Mahallati H, **Hemmelgarn BR**, Manns BJ. The impact of nocturnal hemodialysis and conventional hemodialysis on left ventricular mass and quality of life. *JAMA* 2007;298:1291-1299.
56. Tonelli M, Manns BJ, Culleton BF, Klarenbach SW, **Hemmelgarn BR**, Wiebe N, Jill JS. Association between proximity to the attending nephrologist and mortality among patients receiving hemodialysis. *CMAJ* 2007;177:1039-1044.
57. Leung Y, Panaccione R, **Hemmelgarn BR**, Jones J. Exposing the weaknesses: A systematic review of Azathioprine efficacy in ulcerative colitis. *Dig Dis Sci* 2007;Oct 12
58. Tonelli M, James M, Wiebe N, Jindal K, **Hemmelgarn BR**. Ultrasound monitoring to detect stenosis in hemodialysis patients: A systematic review. *Am J Kidney Dis* 2008;51(4):630-640.

Year 2008

59. James M, Conly J, Manns B, Tonelli M, MacRae J, **Hemmelgarn BR**. Meta-analysis: antibiotics for prophylaxis against hemodialysis catheter related infections. *Ann Intern Med* 2008;148(8):596-605.
60. Ahmed SB, Culleton BF, Tonelli M, Klarenbach, SW, MacRae JM, Zhang J, **Hemmelgarn BR**. Use of postmenopausal hormone therapy and loss of kidney function. *Kidney Int* 2008;74:370-376.
61. Wang W, Tonelli M, **Hemmelgarn BR**, Gao S, Johnson JA, Taub K, Manns B. The effect of increasing dialysis dose in overweight hemodialysis patients on quality of life: a 6-week randomized crossover trial. *Am J Kidney Dis* 2008;51:796-803.
62. **Hemmelgarn BR**, Chen G, Walker R, McAlister FA, Quan H, Tu K, Khan K, Campbell N. Trends in antihypertensive drug prescriptions and physician visits in Canada between 1996 and 2006. *Can J Cardiol* 2008;24:507-512.
63. Tonelli M, Klarenbach S, Wiebe N, Shrive F, **Hemmelgarn BR**, Manns B. Erythropoiesis-stimulating agents for anemia of chronic kidney disease: systematic review and economic evaluation. [Technology report number 106]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008.
64. Padwal RS, **Hemmelgarn BR**, Khan N et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of risk. *Can J Cardiol* 2008;24:455-463.
65. Khan NA, **Hemmelgarn BR**, Herman RJ et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy. *Can J Cardiol* 2008;24:465-472.
66. Gao S, Manns BJ, Culleton BF, Tonelli M, Quan H, Crowshoe L, Ghali WA, Svenson LW, Ahmed S, **Hemmelgarn BR**. Access to health care for status Aboriginal People with chronic kidney disease. *CMAJ* 2008;179:1007-1012.
67. Levin A, **Hemmelgarn BR**, Culleton BF et al. Guidelines for the management of chronic kidney disease: 2008. *CMAJ* 2008;179:1154-1162.
68. James MT, Laupland KB, Tonelli M, Manns BJ, Culleton BF, **Hemmelgarn BR**. Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. *Arch Intern Med* 2008;168:2333-2339.
69. Interdisciplinary Chronic Disease Collaboration. The research to health policy cycle: a tool for better management of chronic noncommunicable disease. *J Nephrol* 2008;21:621-631.

70. James MT, Zhang J, Lyon AW, **Hemmelgarn BR**. Derivation and internal validation of an equation for albumin-adjusted calcium. *BMC Clinical Pathology* 2008;8(1):12.

Year 2009

71. Yeates K, Wiebe N, Gill J, Sima C, Schaubel D, Holland D, **Hemmelgarn BR**, Tonelli M. Similar outcomes among Black and White allograft recipients. *J Am Soc Nephrol* 2009;20:172-179.
72. Kirkpatrick AW, Ball CG, **Hemmelgarn BR**, Zhang J, Ranson K, Zygun D, Keaney M, Groleau M, Tyssen M, Keyte J, Broderick T. Intra-abdominal pressure effects on porcine pulmonary compliance in weightlessness: implications for laparoscopic surgery in space. *Crit Care Med* 2009;37:591-597.
73. Johnson JA, Vermeulen SU, Toth EL, **Hemmelgarn BR**, Ralph-Campbell BA, Hugel G, King M, Crowshoe L. Increasing Incidence and Prevalence of Diabetes among Status Aboriginal Men in Urban and Rural Alberta, 1995-2006. *Can J Public Health* 2009;100:231-236.
74. Manns BJ, Walsh MW, Culleton BF, **Hemmelgarn BR**, Tonelli M, Schorr M, Klarenbach S. Nocturnal hemodialysis does not improve overall quality of life compared to conventional hemodialysis. *Kidney Int* 2009;75:542-549.
75. Chen G, Faris P, **Hemmelgarn BR**, Walker RL, Quan H. Measuring agreement of administrative data with chart data using prevalence unadjusted and adjusted Kappa. *BMC Med Res Methodol* 2009;9:5.
76. Stankus V, **Hemmelgarn BR**, Campbell NRC, Chen G, McAlister FA, Tsuyuki R. Reducing costs and improving hypertension management. *Can J Clin Pharmacol* 2009;e151-e155.
77. Tonelli M, Klarenbach S, Wiebe N, **Hemmelgarn BR**, Reiman A, Reaume N, Lloyd A, Lee H, Manns B. Erythropoiesis-stimulating agents for anemia of cancer or of chemotherapy: systematic review and economic evaluation. [Technology report number H0468]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.
78. Chen G, **Hemmelgarn BR**, Alhaider S, Quan H, Campbell N, Rabi D. Meta-analysis of adverse cardiovascular outcomes associated with antecedent hypertension after myocardial infarction. *Am J Cardiol* 2009;104:141-147.
79. Koshy SM, Garcia-Garcia G, Pamplona JS, Renoirte-Lopez K, Perze-Cortes G, Guitierrez ML, **Hemmelgarn BR**, Lloyd A, Tonelli M. Screening for kidney disease in children on World Kidney Day in Jalisco, Mexico. *Pediatr Nephrol* 2009;24:1219-1225.
80. Vickers MM, Heng DY, **Hemmelgarn BR**, Eigel BJ. Tolerance of Sunitinib in dialyzed patients with metastatic Renal Cell Carcinoma. *Clin Genitourin Cancer* 2009;7:E104-E106.
81. Tonelli M, Wiebe N, **Hemmelgarn BR**, Klarenbach S, Field C, Manns B, Ravi T, Gill J. Trace elements in hemodialysis patients: A systematic review and meta-analysis. *BMC Med* 2009;7:25.
82. Jain A, McLeod I, Huo C, Cuerden M, Akbari A, Tonelli M, van Walraven C, Quinn RR, **Hemmelgarn BR**, Oliver MJ, Ping Li, Garg AX. When laboratories report estimated glomerular filtration rates in addition to serum creatinines, nephrology consults increase. *Kidney Int* 2009;76(3):318-23.
83. James MT, Quan H, Tonelli M, Manns BJ, Faris P, Laupland KB, **Hemmelgarn BR**. CKD and risk of hospitalization and death with pneumonia. *Am J Kidney Dis* 2009;54:24-32.
84. Padwal RS, **Hemmelgarn BR**, Khan NA et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of risk. *Can J Cardiol* 2009;25:279-286.

85. Khan NA, **Hemmelgarn BR**, Herman RJ et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy. *Can J Cardiol* 2009;25:287-298.
86. Tonelli M, **Hemmelgarn BR**, Reiman A, Manns BJ, Reaume MN, Lloyd A, Wiebe N, Klarenbach S. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. *CMAJ* 2009;180:62-71.
87. James MT, Manns BJ, **Hemmelgarn BR**, Ravani P. What's next after "fistula first"? Is an arteriovenous grafts or central venous catheters preferable when an arteriovenous fistula is not possible? *Semin Dial* 2009;22(5):539-44 .
88. Barnieh L, McLaughlin K, Manns B, Klarenbach S, Yilmaz S, **Hemmelgarn BR**. Development of a survey to identify barriers to living donation in kidney transplant candidates. *Progress in Transplantation* 2009;19:304-11.
89. Heitman ST, Ronksley PE, Hilsden RJ, Manns BJ, Rostom A, **Hemmelgarn BR**. Prevalence of adenomas and colorectal cancer in average risk individuals: A systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2009;7:1272-1278.
90. Ronksley PE, Tsai WH, Quan H, Faris P, **Hemmelgarn BR**. Data enhancement for co-morbidity measurement among patients referred for sleep diagnostic testing: an observational study. *BMC Med Res Methodol* 2009;9:50.
91. Deved V, Poyah P, James MT, Tonelli M, Manns BJ, Walsh M, **Hemmelgarn BR**. Ascorbic acid for anemia management in hemodialysis patients: A systematic review and meta-analysis. *Am J Kidney Dis* 2009;54:1089-1097.
92. Walker R, **Hemmelgarn BR**, Quan H. Incidence of gestational hypertension in the Calgary Health Region from 1995 to 2004. *Can J Cardiol* 2009;25(8):e284-7.
93. Ronksley PE, **Hemmelgarn BR**, Heitman SJ, Hanly PJ, Faris PD, Quan H, Tsai WH. Obstructive sleep apnea is associated with diabetes in sleepy subjects. *Thorax* 2009;64:834-839.
94. Tonelli M, Wang W, **Hemmelgarn BR**, Lloyd A, Manns B. Phosphate removal with several thrice weekly dialysis methods in overweight hemodialysis patients. *Am J Kidney Dis*. 2009; 54:1108-1115.
95. Quan H, Khan N, **Hemmelgarn BR**, Tu K, Chen G, Campbell N, Hill MD, Ghali WA, McAlister F. Validation of a case definition to define hypertension using administrative data. *Hypertension* 2009;54:1423-1428.
96. **Hemmelgarn BR**, Clement F, Manns BJ, Klarenbach S, James MT, Ravani P, Pannu N, Ahmed SB, MacRae J, Scott-Douglas N, Jindal K, Quinn R, Culleton BF, Wiebe N, Krause R, Thorlacius L, Tonelli M. Overview of the Alberta Kidney Disease Network. *BMC Nephrology* 2009;10:30.

Year 2010

97. James MT, **Hemmelgarn BR**, Tonelli M. Early recognition and prevention of chronic kidney disease. *Lancet* 2010;375:1296-1309.
98. Walsh M, Sar A, Lee D, Yilmaz S, Benediktsson H, Manns BJ, **Hemmelgarn BR**. Histopathologic features aid in predicting risk of progression of IgA Nephropathy. *Clin J Am Soc Nephrol* 2010;5:425-430.
99. O'Hare AM, Hailpern SM, Pavkov ME, Rios-Burrows N, Gupta I, Maynard C, Todd-Stenberg J, Rodriguez RA, **Hemmelgarn BR**, Saran R, Williams DE. Prognostic implications of the urinary albumin-to-creatinine ratio in Veterans with diabetes of different ages. *Arch Intern Med* 2010;170:930-936.

100. Klarenbach S, Manns BJ, Lee H, Lloyd A, Wiebe N, **Hemmelgarn BR**, Tonelli M, Reaume N, Reiman A. Economic evaluation of erythropoiesis-stimulating agents for anemia related cancer. *Cancer* 2010;116:3224-3232
101. Tai DJ, Lim TW, James MT, Manns BJ, Tonelli M, **Hemmelgarn BR**. Cardiovascular effects of Ace Inhibition or Angiotensin Receptor Blockage in hemodialysis: A meta-analysis. *Clin J Am Soc Nephrol* 2010;5:623-630.
102. **Hemmelgarn BR**, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, Wiebe N, Tonelli M. Relation between kidney function, proteinuria, and adverse outcomes. *JAMA* 2010;303:423-429.
103. Walsh M, Manns BJ, Klarenbach S, Tonelli M, **Hemmelgarn BR**, Culleton B. The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial. *Hemodial Int* 2010;14:174-181.
104. Deyell MW, Ghali WA, Ross DB, Zhang J, **Hemmelgarn BR**. Timing of non-emergent coronary artery bypass grafting and mortality after non-ST-elevation acute coronary syndrome. *Am Heart J* 2010;159(3):490-496.
105. James MT, Wald R, Bell CM, Tonelli M, **Hemmelgarn BR**, Waikar SS, Chertow GM. Weekend hospital admissions with acute kidney injury and mortality. *J Am Soc Nephrol* 2010;21:845-851.
106. Al-Ghamdi G, **Hemmelgarn BR**, Klarenbach S, Manns B, Wiebe N, Tonelli M. Dialysate potassium and risk of death in chronic hemodialysis patients. *J Nephrol* 2010;23:33-40.
107. Ngwakongnwi E, Hemmelgarn BR, Quan H. Documentation of preventive screening interventions by general practitioners: A retrospective chart audit. *BMC Fam Pract* 2010;11:21.
108. Chen G, Khan N, King KK, **Hemmelgarn BR**, Quan H. Home care utilization and outcomes among Asian and other Canadian patients with heart failure. *BMC Cardiovascular Disorders* 2010;10:12.
109. Walker RL, Sykes L, **Hemmelgarn BR**, Quan H. Authors' opinions on publication in relation to annual performance assessment. *BMC Med Educ* 2010;10:21.
110. **Hemmelgarn BR**, Zhang J, Manns BJ, James MT, Quinn RR, Ravani P, Klarenbach SW, Culleton BF, Krause R, Thorlacius L, Jain AK, Tonelli M. Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate. *JAMA* 2010;303:12:1151-1158.
111. Ravani P, Parfrey P, MacRae J, James M, Quinn R, Malberti F, Brunori G, Mandolfo S, Tonelli M, **Hemmelgarn BR**, Manns B, Barrett B. Modeling survival of arteriovenous accesses for hemodialysis: semiparametric versus parametric methods. *Clin J Am Soc Nephrol* 2010; 5:1243-1248.
112. Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, Li Y, Clark SA, Trpkov K, **Hemmelgarn BR**, Beck PL, Muruve DA. The NLRP3 inflammasome regulates renal inflammation and contributes to chronic kidney disease. *J Am Soc Nephrol* 2010;21:1732-1744.
113. Quinn RR, **Hemmelgarn BR**, Padwal RS et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of risk. *Can J Cardiol* 2010;26:241-248.
114. Hackam DG, Khan NA, **Hemmelgarn BR** et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy.

115. Khangura J, Culleton B, Manns B, Zhang J, Walsh M, Klarenbach S, Tonelli M, Barnieh L, Sarna M, **Hemmelgarn BR**. Association between routine and standardized blood pressure measurements and left ventricular hypertrophy among patients on hemodialysis. *BMC Nephrology* 2010;11:13.
116. Jette N, Quan H, **Hemmelgarn BR**, Drosler S, Maas C, Moskal L, Paoiu W, Sundararajan V, Gao S, Jakob R, Ustun B, Ghali W. The development, evolution and modifications of ICD-10: Challenges to the international comparability of morbidity data. *Med Care* 2010;48:1105-1110.
117. James MT, Ghali WA, Tonelli M, Faris P, Knudtson ML, Pannu N, Klarenbach SW, Manns BJ, **Hemmelgarn BR**. Acute kidney injury and long-term decline in kidney function following coronary angiography. *Kidney Int* 2010; 78:803-809.
118. Quinn RR, Laupacis A, Austin PC, Hux JE, Garg AX, **Hemmelgarn BR**, Oliver MJ. Using administrative datasets to study outcomes in dialysis patients: A validation study. *Med Care* 2010;49:745-750.
119. Samuel S, Tonelli M, Foster BJ, Nettel-Aguirre A, Na Y, Williams R, Soo A, **Hemmelgarn BR**. Overview of the Canadian pediatric end-stage renal disease database. *BMC Nephrology* 2010;11:21.
120. Elliott M, Ronksley P, Ahmed S, Clase C, **Hemmelgarn BR**. Acute management of patients with hyperkalemia. *CMAJ* 2010; 182:1631-1635.
121. James MT, **Hemmelgarn BR**, Wiebe N, Pannu N, Manns BJ, Klarenbach SW, Tonelli M. Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury. *Lancet* 2010;376:2096-103.
122. Khan NA, Grubisic M, **Hemmelgarn BR**, Humphries K, King K, Quan H. Outcomes after acute myocardial infarction in South Asian, Chinese and White Patients. *Circulation* 2010;122:1570-1577.
123. Mohan S, Chen G, Campbell NRC, **Hemmelgarn BR**. Regional variations in not treating diagnosed hypertension in Canada. *Can J Cardiol* 2010;26:409-413.
124. Clement FM, Klarenbach S, Tonelli M, Wiebe N, **Hemmelgarn BR**, Manns BJ. An economic evaluation of erythropoiesis-stimulating agents in CKD. *Am J Kidney Dis* 2010;56:1050-1061.
125. Manns BJ, **Hemmelgarn BR**, Tonelli M, Au F, Chiasson TC, Dong J, Klarenbach S. Population based screening for chronic kidney disease: cost effectiveness study. *BMJ* 2010 8;341:c5869.

Year 2011

126. Barnieh L, McLaughlin K, Manns B, Klarenbach S, Yilmaz S, **Hemmelgarn BR**. Barriers to living kidney donation identified by eligible candidates with end-stage renal disease. *Nephrol Dial Transplant* 2011;26:732-738.
127. Rucker D, **Hemmelgarn BR**, Lin M, Manns B, Klarenbach S, Ayyalasomayajula B, James M, Bello Am, Gordon D, Jindal K, Tonelli M. Quality of care and mortality in chronic kidney disease patients living in remote areas. *Kidney Int* 2011;79:210-217.
128. Schorr M, Manns BJ, Culleton B, Walsh M, Klarenbach S, Tonelli M, Sauve L, Chin R, Barnieh L, **Hemmelgarn BR**. The effect of nocturnal and conventional hemodialysis on markers of nutritional status: Results from a randomized trial. *J Renal Nutrition* 2011;21:271-276.
129. James MT, Ghali WA, Knudtson ML, Ravani P, Tonelli M, Faris P, Pannu N, Manns BJ, Klarenbach SW, **Hemmelgarn BR**. Associations between acute kidney injury, cardiovascular and renal outcomes after coronary angiography. *Circulation* 2011;123:409-416.

130. Ronksley P, **Hemmelgarn BR**, Ghali W, Heitman S, Flemons W, Faris P, Manns BJ, Tsai W. Excessive daytime sleepiness is associated with increased health care utilization among patients referred for assessment of OSA. *Sleep* 2011;34:363-370.
131. Kagoma YK, Weir M, Iansavichus AV, **Hemmelgarn BR**, Akbari A, Patel UD, Garg AX, Jain AK. Impact of eGFR reporting on patients, clinicians and health-care systems: A systematic review. *Am J Kidney Dis* 2011;57:592-601.
132. Walker R, Chen G, Campbell N, McAlister FA, Quan H, Tu K, Khan N, **Hemmelgarn BR**. Canadian provincial trends in antihypertensive drug prescriptions between 1996 and 2006. *Can J Cardiol* 2011;27:461-467.
133. **Hemmelgarn BR**, Moist LM, Lok CE, Tonelli M, Manns BJ, Holden RM, LeBlanc M, Faris P, Barre P, Zhang J, Scott-Douglas N. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. *N Engl J Med* 2011;364:303-312.
134. Moist LM, Richards HA, Miskulin D, Lok CE, Yeates K, Garg AX, Trpeski L, Chapman A, Amuah J, **Hemmelgarn BR**. A validation study of the Canadian Organ Replacement Register. *Clin J Am Soc Nephrol* 2011;6:813-818.
135. Tonelli M, Muntner P, Lloyd A, Manns BJ, James MT, Klarenbach S, Quinn RR, Wiebe N, **Hemmelgarn BR**. Using proteinuria and estimated glomerular filtration rate to classify risk in people with chronic kidney disease. *Ann Intern Med* 2011;154:12-21.
136. McAlister F, Zhang J, Tonelli M, Klarenbach S, Manns BJ, **Hemmelgarn BR**. The safety of combination therapy with angiotensin converting enzyme inhibitors and angiotensin receptor blockers in elderly individuals: population based longitudinal analysis. *CMAJ* 2011;183:655-662.
137. Samuel S, Tonelli M, Foster B, Alexander RT, Nettel-Aguirre A, Soo A, **Hemmelgarn BR**. Survival in pediatric dialysis and transplant patients. *Clin J Am Soc Nephrol* 2011;6:1094-1099.
138. Barnieh L, McLaughlin K, Manns BJ, Klarenbach S, Yilmaz S, Taub K, **Hemmelgarn BR**. Evaluation of an education intervention to increase the pursuit of living kidney donation: a randomized controlled trial. *Prog Transplant* 2011;21:36-42.
139. Chen G, McAlister FA, Walker RL, **Hemmelgarn BR**, Campbell NRC. Cardiovascular outcomes in Framingham participants with diabetes: The importance of blood pressure. *Hypertension* 2011;57:891-897.
140. Jones SM, Ravani P, **Hemmelgarn BR**, Muruve D, MacRae JM. Morphometric and biological characterization of biofilm in tunneled hemodialysis catheters. *Am J Kidney Dis* 2011;57:449-455.
141. Jain A, **Hemmelgarn BR**. Impact of estimated glomerular filtration rate reporting on nephrology referrals: a review of the literature. *Curr Opin Nephrol Hypertens* 2011;20:218-223.
142. Barnieh L, James MT, Zhang J, **Hemmelgarn BR**. Propensity score methods and their application in nephrology research. *J Nephrol* 2011;24:256-262.
143. Bello AK, Thadhani R, **Hemmelgarn BR**, Klarenbach S, Gill J, Chan C, Zimmerman D, Holmes D, Cembrowski G, Opengorth D, Sibrian R, Karkhaneh M, Tiv S, Wiebe N, Tonelli M. Design and implementation of the Canadian Kidney disease Cohort Study (CKDCS): A prospective observational study of incident HD patients. *BMC Nephrology* 2011;12:10.
144. Clement FM, James MT, Chin R, Klarenbach SW, Manns BJ, Quinn RR, Ravani P, Tonelli M, **Hemmelgarn BR**. Validation of a case definition to define chronic dialysis using outpatient administrative data. *BMC Medical Research Methodology* 2011;11:25.

145. Barnieh L, Manns BJ, Klarenbach S, McLaughlin K, Yilmaz S, **Hemmelgarn BR**. A description of the costs of living and standard criteria deceased donor kidney transplantation. *Am J Transplant* 2011;11:478-488.
146. Ahmed SB, Ronksley PE, **Hemmelgarn BR**, Tsai WH, Manns BJ, Tonelli M, Klarenbach SW, Clement FM, Hanly PJ. Nocturnal hypoxia and loss of kidney function. *PLoS One* 2011;29:e19029.
147. Samuel S, Nettel-Aguirre A, **Hemmelgarn BR**, Tonelli M, Soo A, Clark C, Alexander RT, Foster BJ. Graft failure and adaptation period to adult health care centers in pediatric renal transplant patients. *Transplantation* 2011;91:1380-1385.
148. Pannu N, James M, **Hemmelgarn BR**, Dong J, Tonelli M, Klarenbach S. Modification of Outcomes After Acute Kidney Injury by the Presence of CKD. *Am J Kidney Dis*. 2011;58:206-213.
149. Oster R, Johnson J, **Hemmelgarn BR**, King M, Balko S, Svenson L, Crowshoe L, Toth E. Recent epidemiologic trends of diabetes among adult Status Aboriginal Population of Alberta. *CMAJ* 2011;183:E803-808.
150. Armstrong MJ, Mottershead T, Ronksley PE, Sigal RJ, Campbell T, **Hemmelgarn BR**. Motivational interviewing to improve weight loss in overweight and/or obese patients: a systematic review and meta-analysis of randomized controlled trials. *Obes Rev* 2011;12:709-723..
151. Bello AK, **Hemmelgarn BR**, Lloyd A, James MT, Manns BJ, Klarenbach S, Tonelli M. Associations between estimated glomerular filtration rate, proteinuria and adverse cardiovascular outcomes. *Clin J Am Soc Nephrol* 2011;6:1418-1426.
152. Tonelli M, Klarenbach SW, Lloyd A, James MT, Bello A, Manns BJ, **Hemmelgarn BR**. Higher estimated glomerular filtration rates may be associated with increased risk of adverse outcomes, especially with concomitant proteinuria. *Kidney Int* 2011;80:1306-1314.
153. Ayyalasomayajula B, Wiebe N, **Hemmelgarn BR**, Bello A, Manns B, Klarenbach S, Tonelli M. A novel technique to optimize facility locations of new nephrology services for remote areas. *Clin J Am Soc Nephrol* 2011;6:2157-2164.
154. Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, Myers MG, McKay DW, Quinn RR, **Hemmelgarn BR** et al. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. *Can J Cardiol* 2011;27:415-433.
155. Shurraw S, Hemmelgarn BR, Lin M, Majumdar SR, Klarenbach S, Manns B, Bello A, James M, Turin TC, Tonelli M. Association between glycemic control and adverse outcomes in people with diabetes and chronic kidney disease: population-based cohort study. *Arch Intern Med* 2011;171:1920-1927.
156. Van der Velde M, Matsushita K, Coresh J, **Hemmelgarn BR**, Manley T. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. *Kidney Int* 2011;79:1341-1352.
157. Thomson BKA, MacRae JM, Barnieh L, Zhang J, MacKay E, Manning MA, **Hemmelgarn BR**. Evaluation of an electronic warfarin nomogram for anticoagulation of hemodialysis patients. *BMC Nephrology* 2011, 12:46.
158. Conly J, Clement F, Tonelli M, **Hemmelgarn BR**, Klarenbach S, Lloyd A, McAlister FA, Husereau D, Wiebe N, Au F, Manns B. Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. *CMAJ* 2011;183:E1180-8.

159. Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, **Hemmelgarn BR**, Klarenbach S, McAlister FA, Wiebe N, Manns B. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. *CMAJ* 2011;183:E1189-802.
160. Samuel SM, Foster BJ, Tonelli M, Nettel-Aguirre A, Soo A, Alexander RT, Crowshoe L, **Hemmelgarn BR**. Dialysis and transplantation among Aboriginal children with kidney failure. *CMAJ* 2011;183:E665-72.
161. Ronksley PE, **Hemmelgarn BR**, Tsai W. Co-morbidity and healthcare costs in patients with OSA. *Breathe* 2011;8(2):95-104.

Year 2012

162. Nicholl DD, **Hemmelgarn BR**, Turin T, MacRae J, Muruve D, Sola D, Ahmed S. Increased urinary protein excretion in the “normal” range is associated with increased rennin angiotensin system activity. *Am J Physiol Renal Physiol* 2012;302:F526-532.
163. Bello A, Thompson S, Lloyd A, **Hemmelgarn BR**, Klarenbach S, Manns B, Tonelli M. Multiple versus single and other estimates of baseline proteinuria status as predictors of adverse outcomes in the general population. *Am J Kidney Dis* 2012;59:364-371.
164. Barnabe C, Joseph L, Belisle P, Labrecque J, Edworthy S, Barr S, Fritzler M, Svenson L, **Hemmelgarn BR**, Bernatsky S. Increased Prevalence of Systemic Lupus Erythematosus and Systemic Sclerosis in Alberta’s First Nations Population. *Arthritis Care Res* 2012;64:138-143.
165. Inker LA, Tonelli M, **Hemmelgarn BR**, Levitan EB, Muntner P. Comparison of concurrent complications of CKD by two risk categorization systems. *Am J Kidney Dis* 2012;59:372-381.
166. Manns B, Tonelli M, Zhang J, Campbell D, Sargious P, Ayyalaso B, Clement F, Johnson J, Laupacis A, Lewanczuk R, McBrien K, **Hemmelgarn BR**. Enrolment in primary care networks: impact on outcomes and process of care in patients with diabetes. *CMAJ* 2012;2012;184:E144-152.
167. Ronksley PE, Tonelli M, Quan H, Manns BJ, James MT, Clement FM, Samuel S, Quinn RR, Ravani P, Brar SS, **Hemmelgarn BR**. Validating a Case Definition for Chronic Kidney Disease using Administrative Data. *Nephrol Dial Transplant*. 2012;27:1826-1831.
168. Kiss Val, Pim C, **Hemmelgarn BR**, Quan H. Building knowledge about health services utilization by refugees. *J Immigr Minor Health* 2013;15(1):57-67.
169. Ngwakongnwi E, King K, **Hemmelgarn BR**, Musto R, Quan H. Language barrier and having and using regular medical doctors by Canada’s official language minorities. *Canadian Family Physician* 2012;58:e709-e716.
170. Wiebe N, Klarenbach SW, Chui B, Ayyalasomayajula B, **Hemmelgarn BR**, Jindal K, Manns B, Tonelli M. Adding specialized clinics for remote-dwellers with chronic kidney disease: A cost-utility analysis. *Clin J Am Soc Nephrol* 2012;7:24-34.
171. Nicholl D, Ahmed S, Loewen A, **Hemmelgarn BR**, Sola D, Beecroft J, Turin TC, Hanly P. Declining kidney function increases the prevalence of sleep apnea and nocturnal hypoxia. *Chest* 2012;141:1422-1430.
172. Stelfox HT, **Hemmelgarn BR**, Bagshaw S, Gao S, Doig C, Nijssen-Jordan C, Manns BJ. ICU bed availability and outcomes for hospitalized patients with sudden clinical deterioration. *Arch Intern Med* 2012;172:476-474.
173. Ronksley PE, Sanmartin C, Quan H, Ravani P, Tonelli M, Manns BJ, **Hemmelgarn BR**. Association between chronic disease and perceived unmet health care needs. *Open Medicine* 2012;6:e48.

174. Mann, M, Exner D, **Hemmelgarn BR**, Turin TC, Sola D, Ahmed S. Impact of gender on the cardiac autonomic response to Angiotensin II in healthy humans. *Journal of Applied Physiology* 2012;112:1001-1007.
175. Turin TC, Tonelli M, Manns B, Ravani P, Ahmed SB, **Hemmelgarn BR**. Chronic kidney disease and life expectancy. *Nephrol Dial Transplant* 2012;27:3182-3186.
176. Ronksley PE, Hemmelgarn BR. Optimizing care for patients with chronic kidney disease. *Am J Kidney Dis* 2012;60:133-138.
177. Campbell NR, **Hemmelgarn BR**. New recommendations for the use of ambulatory blood pressure monitoring in the diagnosis of hypertension. *CMAJ* 2012;184:633-634.
178. Conley J, Tonelli M, Quan H, Manns BJ, Palacios-Derflinger L, Bresee LC, Khan N, **Hemmelgarn BR**. Association between glomerular filtration rate, proteinuria and adverse outcomes among White, Chinese and South Asian individuals in Canada. *Am J Kidney Dis* 2012;59:390-399.
179. Samuel S, **Hemmelgarn BR**, Nettel-Aguirre A, Foster B, Soo A, Alexander T, Tonelli M. Association between residence location and likelihood of transplantation among pediatric dialysis patients. *Pediatric Transplantation* 2012;10:1399-3046.
180. Manns BJ, Tonelli M, Culleton B, Faris P, McLaughlin K, Chin R, Gooch K, McAlister FA, Taub K, Thorlacius L, Krause R, Kearns M, **Hemmelgarn BR**. A cluster randomized trial of an enhanced eGFR prompt in chronic kidney disease. *Clin J Am Soc Nephrol* 2012;7:565-572.
181. Matsushita K, Tonelli M, Lloyd A, Levey AS, Coresh J, Hemmelgarn BR. Clinical risk implications of the CKD-EPI equation compared to the MDRD study equation for estimated glomerular filtration rate. *Am J Kidney Dis* 2012;60:214-249.
182. Jain AK, Cuerden MS, McLeod I, **Hemmelgarn BR**, Tonelli M, Quinn RR, Oliver MJ, Garg AX. Reporting of the estimated glomerular filtration rate was associated with increased use of angiotensin-converting inhibitors and angiotensin-II receptor blockers in CKD. *Kidney Int* 2012;81:1248-1253
183. Tonelli M, Muntner P, Lloyd A, Manns B, Klarenbach S, Pannu N, James M, **Hemmelgarn BR**. Risk of future coronary events among people with chronic kidney disease as compared to those with diabetes: a population-level cohort study. *The Lancet* 2012;380:807-814.
184. Alexander RT, Foster B, Tonelli M, Soo A, Nettel-Aguirre A, **Hemmelgarn BR**, Samuel S. Survival and transplantation outcomes of children less than 2 years of age with end-stage renal disease. *Pediatric Nephrol* 2012;27:1975-1983.
185. Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, Polkinghorne KR, Shankar A, Smith DH, Tonelli M, Warnock DG, Wen CP, Coresh J, Gansevoort RT, Hemmelgarn BR, Levey AS. Comparison of risk prediction using the CKD-EPI equation and the MDRD Study equation for estimated glomerular filtration rate. *JAMA* 2012;307:1941-51.
186. Lok CE, Moist L, **Hemmelgarn BR**, Tonelli M, Vazquez MA, Dorval M, Oliver M, Donnelly S, Allon M, Stanley K. Effect of Fish Oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts. *JAMA* 2012;307:1809-1816.
187. St.Germaine-Smith C, Metcalfe A, Pringsheim T, Roberts JI, Beck C, **Hemmelgarn BR**, McChesney J, Quan H, Jette N. Recommendations for optimal ICD codes to study neurological conditions: A systematic review. *Neurology* 2012;4:1049-1055.
188. Tricco AC, Soobiah C, Lillie E, Perrier L, Chen MH, **Hemmelgarn BR**, Majumdar SR, Straus SE. Use of cognitive enhancers for mild cognitive impairment: Protocol for a systematic review and network meta-analysis. *Systematic Reviews* 2012, 1:25.

189. Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong P, Farmer CKT, Matsushita K, **Hemmelgarn BR**. One-year change in kidney function is associated with an increased mortality risk. *Am J Nephrol* 2012;14:41-49.
190. Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong P, Farmer CKT, Matsushita K, **Hemmelgarn BR**. Short-term change in kidney function and risk of end-stage renal disease. *Nephrol Dial Transplant* 2012;27:3835-43.
191. MacRae J, Ahmed S, **Hemmelgarn BR**. A randomized controlled trial comparing buttonhole to rope ladder needling in conventional hemodialysis patients. *Clin J Am Soc Nephrol* 2012;7:1632-1638.
192. Daskalopoulou SS, Khan NA, Quinn RR, Ruzicka M, **Hemmelgarn BR**, Tobe SW. The 2012 Canadian Hypertension Education Program recommendations for the management of hypertension: Blood pressure measurement, diagnosis, assessment of risk and therapy. *Can J Cardiol* 2012;28:270-287.
193. Barnabe C, Joseph L, Belisle P, Labrecque J, Barr SG, Fritzler MJ, Svenson LW, Peschken CA, **Hemmelgarn BR**, Bernatsky S. Prevalence of autoimmune inflammatory myopathy in Alberta's First Nations population. *Arthritis Care Res* 2012;64:1715-1719.
194. Turin TC, **Hemmelgarn BR**. Long-term risk projection and their application in nephrology research. *J Nephrol* 2012; 25:441-9.
195. **Hemmelgarn BR**, James MT, Manns BJ, O'Hare AM, Muntner P, Ravani P, Quinn RR, Turin TC, Tan Z, Tonelli M. Rates of treated and untreated kidney failure in older vs younger adults. *JAMA* 2012;307:2507-2515.
196. Turin TC, Tonelli M, Manns BJ, Ahmed SB, Ravani P, James M, **Hemmelgarn BR**. Lifetime risk of ESRD. *J Am Soc Nephrol* 2012;23:1569-1578.
197. Nichol D, Ahmed S, Loewen A, **Hemmelgarn BR**, Beecroft J, Sola D, Turin TC, Hanly P. Clinical presentation of obstructive sleep apnea in patients with chronic kidney disease. *J Clin Sleep Med* 2012; 15:381-7.
198. Tai DJ, Conley J, Ravani P, **Hemmelgarn BR**, MacRae JM. Hemodialysis prescription education decreases intradialytic hypotension. *J Nephrol* 2012;26(2);315-22.
199. Bello A, **Hemmelgarn BR**, Manns B, Tonelli M. Use of administrative databases for health-care planning in CKD. *Nephrol Dial Transplant* 2012;27 Suppl 3:iii12-iii18.
200. Samuel S, Foster BJ, **Hemmelgarn BR**, Nettel-Aguirre A, Crowshoe L, Alexander RT, Soo A, Tonelli M. Incidence and causes of end-stage renal disease among Aboriginal and Caucasians. *CMAJ* 2012;184:E758-64.
201. Alexander RT, **Hemmelgarn BR**, Wiebe N, Bello A, Morgan C, Samuel S, Klarenbach SW, Curhan GC, Tonelli M. Kidney stones and kidney function loss: A cohort study. *BMJ* 2012;345:e5287.
202. Sood MM, **Hemmelgarn BR**, Yeates K, Tangri N, Komenda P, Rigatto C, Mojica J. Association of modality with mortality among Canadian Aboriginals. *Clin J Am Soc Nephrol* 2012;7:1988-1995.
203. McBrien K, Rabi DM, Campbell N, Barnieh L, Clement F, **Hemmelgarn BR**, Tonelli M, Letier LA, Klarenbach SW, Manns BJ. Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: Systematic review and meta-analysis. *Arch Intern Med* 2012;6:1-8.
204. Faruque LI, Ayyalasomayajula B, Pelletier R, Klarenbach S, **Hemmelgarn BR**, Tonelli M. Spatial analysis to locate new clinics for diabetic kidney patients in underserved communities in Alberta. *Nephrol Dial Transplant* 2012;27:4102-4109.

205. Bass A, Ahmed DB, Klarenbach S, Culleton B, **Hemmelgarn BR**, Manns B. The impact of nocturnal hemodialysis on sexual function. *BMC Nephrol* 2012;13:67.
206. Manns BJ, Laupland K, Tonelli M, Gao S, **Hemmelgarn BR**. Evaluating the impact of a novel restricted reimbursement policy for quinolone antibiotics: A time series analysis. *BMC Health Serv Res* 2012;30:290.
207. Suissa S, Henry D, Caetano P, Dormuth CR, Ernst P, **Hemmelgarn BR**, LeLorier J, Levy A, Martens PJ, Paterson MJ, Platt RW, Sketris I, Teare G. CNODES: The Canadian Network for Observational Drug Effect Studies. *Open Medicine* 2012;6(4):134-140.
208. Matsushita K, Ballew SH, Astor BC, de Jong P, Gansevoort RT, **Hemmelgarn BR**, Levey AS, Levin A, Wen CP, Woodward M, Coresh J. Cohort profile: The Chronic Kidney Disease Prognosis Consortium. *Int J Epidemiol* 2012;1-9.
209. **Hemmelgarn BR**, Manns BJ, Straus S, Naugler C, Holroyd-Leduc J, Braun TC, Levin A, Klarenbach S, Lee PF, Hafez K, Schwartz D, Jindal K, Ervin K, Bello A, Turin TC, McBrien K, Elliott M, Tonelli M. Knowledge translation for nephrologists: strategies for improving the identification of patients with proteinuria. *Nephrol Dial Transplant* 2012;25:933-943.
210. Ngwakongnwi E, **Hemmelgarn BR**, Musto R, Quan H, King-Shier KM. Experiences of French speaking immigrants and non-immigrants accessing health care services in a large Canadian city. *Int J Environ Res Public Health* 2012;9:3755-3768.
211. McBrien KA, Manns BJ, Chui B, Klarenbach SW, Rabi D, Ravani P, **Hemmelgarn BR**, Wiebe N, Au F, Clement F. Health care costs in people with diabetes and their association with glycemic control and kidney function. *Diabetes Care* 2012;36(5):1172-1180.
212. Thompson S, **Hemmelgarn BR**, Wiebe N, Majumdar S, Klarenbach S, Jindal K, Manns B, Mortis G, Campbell P, Tonelli M. Clinical decision support to improve blood pressure control in hemodialysis: a nonrandomized controlled trial. *J Nephrol* 2012;25:944-953.
213. Campbell DJT, Ronksley PE, **Hemmelgarn BR**, Zhang J, Barnabe C, Tonelli M, Manns B. Association of enrollment in primary care networks with care and outcomes among First Nations and low-income Alberta. *Open Med* 2012;6:e155-e165.
214. de Koning L, Henne D, **Hemmelgarn BR**, Woods P, Naugler C. Non-linear relationship between serum 25-hydroxyvitamin D concentration and subsequent hip fracture. *Osteoporosis Int* 2012;24(7):2061-2065.

YEAR 2013

215. Turin TC, Tonelli M, Manns BJ, Ahmed SB, Ravani P, James MT, **Hemmelgarn BR**. Proteinuria and life expectancy. *Am J Kidney Dis* 2013;61(4):646-8.
216. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Inter Suppl* 2013;3:1-150.
217. Nicholl DD, Ahmed SB, Loewen AH, **Hemmelgarn BR**, Sola DY, Beecroft JM, Turin TC, Hanly PJ. Diagnostic value of screening instruments for identifying obstructive sleep apnea in kidney failure. *J Clin Sleep Med* 2013 9:(1)31-8.
218. Quan H, Chen C, Tu K, Bartlett G, Butt DA, Campbell NRC, **Hemmelgarn BR**, Hill MD, Johansen H, Khan N, Lix LM, Smith M, Svenson L, Walker RL, Wielgosz A, McAlister FA for Hypertension Outcome and Surveillance Team. Outcomes among 3.5 million newly diagnosed hypertensive Canadians. *Canadian Journal of Cardiology* 2013;29(5):592-597.
219. Ward D, Novak E, Brar S, White MT, Scott-Douglas N, **Hemmelgarn BR**. An assessment of the Siksika Chronic Disease Nephropathy Prevention Clinic. *Canadian Family Physician* 2013;59:(1)e19-25.

220. Ravani P, Palmer SC, Oliver MJ, Quinn RR, MacRae JM, Tai DJ, Pannu NI, Thomas C, **Hemmelgarn BR**, Craig JC, Manns B, Tonelli M, Strippoli GFM, James MT. Association between hemodialysis vascular access type and clinical outcomes: Meta-analysis of cohort studies. *J Am Soc Nephrol* 2013;24(3):465-473.
221. Quan H, Chen G, Walker RL, Wielgosz A, Dai S, Tu K, Campbell NRC, **Hemmelgarn BR**, Hill MD, Johansen H, McAlister FA, Khan N. Incidence, cardiovascular complications and mortality of hypertension by sex and ethnicity. *Heart* 2013;99(1):715-721.
222. Nitsch D, Grams M, Yingying S, Black C, Cirillo M, Djurdjev O, Iseki K, Jassal SK, Kimm H, Kronenberg F, Oien CM, Levey AS, Levin A, Woodward M, **Hemmelgarn BR**. Do the associations of eGFR and albuminuria with mortality and renal failure differ by gender? A meta-analysis from a global consortium. *BMJ* 2013;346:f324.
223. Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong P, Farmer CKT, Matsushita K, **Hemmelgarn BR**. Change in estimated glomerular filtration rate over time and risk of death. *Kidney Int* 2013; 83(4):684-691.
224. Promislow S, **Hemmelgarn BR**, Rigatto C, Tangri N, Yeates K, Mojica J, Komenda P, Sood MM. Young Aboriginals with ESRD are less likely to receive a renal transplant: A Canadian National study. *BMC Nephrol* 2013;14:11.
225. James MT, Samuel SM, Manning MA, Tonelli M, Ghali WA, Faris P, Knudtson ML, Pannu N, **Hemmelgarn BR**. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography. *Circ Cardiovasc Interv* 2013;6(1):37-43.
226. Dormuth CR, **Hemmelgarn BR**, Paterson JM, James MT, Teare GF, Raymond CB, Levy AR, Garg AX, Ernst P, for the CNODES investigators. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. *BMJ* 2013;346:f880
227. Elliott M, Tam H, **Hemmelgarn BR**. Age and treatment of kidney failure. *Current Opinion in Nephrology and Hypertension* 2013;22:344-350.
228. Deved V, Jette N, Quan H, Tonelli M, Manns BJ, Soo A, Barnabe C, **Hemmelgarn BR**. Quality of care for First Nations and non-First Nations with diabetes. *Clin J Am Soc Nephrol* 2013;8(7):1188-1194.
229. Campbell DJT, Sargious P, Lewanczuk R, McBrien K, Tonelli M, **Hemmelgarn BR**, Manns BJ. Use of chronic disease management programs for diabetes in Alberta's primary care networks. *Can Fam Physician* 2013;59(2):e86-92.
230. Pannu N, James MT, **Hemmelgarn BR**, Klarenbach S. Association between acute kidney injury, recovery of renal function and long-term outcomes after hospital discharge. *Clin J Am Soc Nephrol* 2013;8(2):194-202.
231. Gansevoort RT, Correa-Rotter, **Hemmelgarn BR**, Matsushita K, Lambers Heerspink HJ, Jafar TH, Mann J, Wen CP. Chronic kidney disease amplifies cardiovascular risk: Impact, mechanisms and prevention. *Lancet* 2013;382(9889):339-352.
232. Tricco AC, Antony J, Soobiah C, **Hemmelgarn BR**, Moher D, Hutton B, Yu CH, Majumdar SR, Straus SE. Safety, effectiveness, and cost of dipeptidyl peptidase-4 inhibitors versus intermediate acting insulin for type 2 diabetes: Protocol for a systematic review and network meta-analysis. *Systematic Reviews* 2013, 2:47
233. Tricco AC, Antony J, Soobiah C, **Hemmelgarn BR**, Moher D, Hutton B, Yu CH, Majumdar SR, Straus SE. Safety, effectiveness and cost of long-acting versus intermediate-acting insulin for type 1 diabetes: Protocol for a systematic review and network meta-analysis. *Systematic Reviews* 2013;2:73.

234. Tricco AC, Antony J, Soobiah C, **Hemmelgarn BR**, Moher D, Hutton B, Straus SE. Safety of serotonin (5-HT₃) receptor antagonists in patients undergoing surgery and chemotherapy: Protocol for a systematic review and network meta-analysis. *Systematic Reviews* 2013, 2:46.
235. Tricco AC, Soobiah C, Antony J, **Hemmelgarn BR**, Moher D, Hutton B, Straus SE. Interventions to decrease the risk of adverse cardiac events for post-surgery or chemotherapy patients taking serotonin (5-HT₃) receptor antagonists: Protocol for a systematic review and network meta-analysis. *Systematic Reviews* 2013, 2:45
236. Thompson S, Bello A, Wiebe N, Manns B, **Hemmelgarn BR**, Klarenbach S, Pelletier R, Tonelli M. Quality of care indicators among remote-dwelling hemodialysis patients: A cohort study. *Am J Kidney Dis.* 2013;62(2):295-303.
237. Naugler C, Zhang J, Henne D, Woods P, **Hemmelgarn BR**. Association of vitamin D status with socio-demographic factors in Calgary, Alberta: an ecological study using Census Canada data. *BMC Public Health* 2013;13:316.
238. Elliott M, James MT, Quinn RR, Ravani P, Tonelli M, Palacios-Derflingher L, Tan Z, Manns B, Kline GA, Ronksley PE, **Hemmelgarn BR**. Estimated glomerular filtration rate and fracture risks: a population-based study. *Clin J Am Soc Nephrol* 2013; 8:1367-1376.
239. Bello A, Wiebe N, **Hemmelgarn BR**, Manns B, Klarenbach S, Thompson S, Pelletier R, Tonelli M. A population-based study on care and clinical outcomes in remote dwellers with heavy proteinuria. *Kidney Int* 2013;3(2)254-258.
240. Walker RL, Chen G, McAlister FA, Campbell NRC, Hemmelgarn BR, Dixon E, Ghali W, Rabi D, Tu K, Jette N, Quan H. Hospitalization for uncomplicated hypertension: an ambulatory care sensitive condition. *Canadian Journal of Cardiology* 2013;29(11):1462-1469.
241. Turin TC, James M, Ravani P, Tonelli M, Manns BJ, Quinn R, Jun M, Klarenbach S, **Hemmelgarn BR**. Proteinuria and rate of change in kidney function in a community based population. *J Am Soc Nephrol* 2013;(10):1661-7.
242. Ravani P, Gillespie B, Quinn R, MacRae J, Mendelssohn D, Tonelli M, **Hemmelgarn BR**, James M, Pannu N, Robinson B, Zhang X, Pisoni R. Temporal risk profile for infectious and non-infectious complications of hemodialysis access. *J Am Soc Nephrol* 2013;24(10):1668-1677.
243. Schorr M, **Hemmelgarn BR**, Manns B, Tonelli M, Soo A, Bresee L. Assessment of serum creatinine and kidney function among incident metformin users. *Canadian J of Diabetes* 2013;37:226-230.
244. Lee J, Nichol D, Ahmed S, Lowen A, **Hemmelgarn BR**, Chowdhury TC, Beecroft J, Hanly P. Prevalence of restless legs syndrome in patients with chronic kidney disease. *J Clin Sleep Med* 2013;9(5):455-459.
245. Ronksley PE, Sanmartin C, Quan H, Ravani P, Tonelli M, Manns B, **Hemmelgarn BR**. Association between perceived unmet health care need and risk of adverse health outcomes among patients with chronic medical conditions. *Open Medicine* 2013;7(1):e21-e30.
246. Tonelli M, Muntner P, Lloyd A, Manns B, Klarenbach S, Pannu N, James M, **Hemmelgarn BR**. Association between LDL-C and risk of myocardial infarction in CKD. *J Am Soc Nephrol* 2013;24(6):870-872.
247. Mann M, Exner D, **Hemmelgarn BR**, Sola D, Turin T, Ellis L Ahmed S. Vitamin D levels are associated with cardiac autonomic activity in healthy humans. *Nutrients* 2013;5(6):2114-2127.
248. James MT, Tonelli M, Ghali WA, Knudtson ML, Faris P, Manns BJ, Pannu N, Galbraith PD, **Hemmelgarn BR**. Renal Outcomes Associated with Invasive versus Conservative

Management of Acute Coronary Syndrome: Propensity-matched Cohort Study. *BMJ* 2013;347:f4151

249. Majumdar SR, **Hemmelgarn BR**, Lin M, McBrien K, Manns BJ, Tonelli M. Hypoglycemia associated with hospitalization and adverse events in older people: population-based cohort study. *Diabetes Care* 2013;36(11):3585-90.
250. Tricco A, Soobiah C, Berliner S, Ho JM, Ng CH, Ashoor HM, Chen MH, **Hemmelgarn BR**, Straus SE. Efficacy and safety of cognitive enhancers for mild cognitive impairment: a systematic review and meta-analysis. *CMAJ* 2013;185(16):1393-401.
251. Wong BC, Ravani P, Manns BJ, Lewin A, Zhang X, Chin R, **Hemmelgarn BR**, Tonelli M, Oliver MJ, Quinn RR. Association of a change in erythropoiesis-stimulating agent dose during hospitalization and subsequent haemoglobin levels and transfusions in hemodialysis patients. *Am J Kidney Dis* 2013;62(5):947-52.
252. Faruque LI, **Hemmelgarn BR**, Wiebe N, Manns BJ, Ravani P, Klarenbach S, Pelletier R, Tonelli M. Factors associated with initiation of chronic renal replacement therapy for patients with kidney failure. *Clin J Am Soc Nephrol* 2013;8(8):1327-35.
253. Tam, H Cepoiu M, Ronksley P, Maxwell C, **Hemmelgarn BR**. Dementia case management and risk of long-term care placement: a systematic review and meta-analysis. *International Journal of Geriatric Psychiatry* 2013;28(9):889-902.
254. Ahmed AA, Nicholl D, **Hemmelgarn BR**, MacRae J, Sola D, Ahmed SB. 25-hydroxyvitamin D status, arterial stiffness and the renin angiotensin system in healthy humans. *Clin Exp Hypertens* 2013:1-6
255. Manns BJ, Braun T, Edwards A, Grimshaw J, **Hemmelgarn BR**, Husereau D, Ivers N, Johnson J, Long S, McBrien K, Naugler C, Sargious P, Straus S, Tonelli M, Tricco A, Yu C. Identifying strategies to improve diabetes care in Alberta, Canada using the knowledge-to-action cycle: Results of a collaborative workshop. *CMAJ Open* 2013;1:E1420E150.
256. Ahmed AA, Mann M, **Hemmelgarn BR**, MacRae J, Sola D, Turin TC, Benediktsson H, Ahmed SB. IgA nephropathy with early kidney disease is associated with increased arterial stiffness and renin angiotensin system activity. *Journal of the Renin-Angiotensin-Aldosterone System*. 2013 0(0)1-8.
257. Bello A, Padwal R, Lloyd A, **Hemmelgarn BR**, Klarenbach S, Manns B, Tonelli M. Using linked administrative data to study periprocedural mortality in obesity and chronic kidney disease. *Nephrol Dial Transplant* 2013;28(5):IV54-IV64.
258. Ronksley PE, Ravani P, Sanmartin C, Quan H, Manns B, Tonelli M, **Hemmelgarn BR**. Patterns of engagement with the health care system and risk of subsequent rehospitalization amongst patients with diabetes. *BMC Health Services Research* 2013;13:399.

YEAR 2014

259. Alexander T, **Hemmelgarn BR**, Wiebe N, Bello A, Samuel S, Klarenbach SW, Curhan GC, Tonelli M. Kidney stones and cardiovascular events: A cohort study. *Clin J Am Soc Nephrol* 2014;9:506-12.
260. Zalucky AA, Nicholl DDM, Mann MC, Hemmelgarn BR, Turin TC, MacRae JM, Sola D, Ahmed SB. Sex influences the effect of body mass index on the vascular response to angiotensin II in humans. *Obesity* 2014;22(3):739-46.
261. Klarenbach SW, Culleton B, Tonelli M, Pauly R, So H, Walsh M, **Hemmelgarn BR**, Manns BJ. Economic evaluation of frequent home nocturnal hemodialysis based on a randomized controlled trial. *J Am Soc Nephrol* 2014;25(3):587-94.

262. Ronksley PE, Sanmartin C, Campbell DJT, Weaver RG, Allan GM, McBrien K, Tonelli M, Manns B, Hennessy D, **Hemmelgarn BR**. Perceived barriers to primary care among Western Canadians with chronic disease. *Health Rep.* 2014;25:3-10.
263. MacRae JM, Ahmed SB, **Hemmelgarn BR**. Buttonhole cannulation technique as the cannulation method of choice. *Am J Kidney Disease* 2014;63(1):165.
264. Ehteshami-Afshar A, Weaver, R, Lin M, Allan M, Sanmartin C, Lewanszuk R, Manns BJ, **Hemmelgarn BR**, Tonelli M. Willingness to use different types of information technology among patients with chronic non-communicable disease. *CMAJ Open* 2014;2(2):E51-E59.
265. Samuel S, Nettel-Aguirre A, Soo A, **Hemmelgarn BR**, Tonelli M, Foster B. Avoidable hospitalization in youth with kidney failure after transfer to or with only adult care. *Pediatrics* 2014;133(4):e993-1000.
266. Campbell DJT, King-Shier K, **Hemmelgarn BR**, Ronksley PE, Sanmartin C, Weaver RG, Tonelli M, Hennessy D, Manns BJ. The association between financial barriers and care and outcomes for patients with chronic disease. *Health Reports* 2014 25:3-12.
267. Barnieh L, **Hemmelgarn BR**, Klarenbach S, Yilmaz S, McLaughlin K, Manns BJ. The cost of kidney transplantation over time. *Progress in Transplantation* 2014;24(3):257-62.
268. Mann M, Exner D, Chowdhury TC, **Hemmelgarn BR**, Sola D, Ellis L, Ahmed SB. Vitamin D supplementation is associated with improved modulation of cardiac autonomic tone in health humans. *Int J Cardiol* 2014;172(2):506-508.
269. Bello A, Stenvinkel P, Lin M, **Hemmelgarn BR**, Thadhani R, Klarenbach S, Chan C, Zimmerman D, Cembrowski G, Strippoli G, Carrero JJ, Tonelli M. Serum testosterone levels and clinical outcomes in male hemodialysis patients. *Am J Kidney Dis* 2014;63(2):268-275.
270. O'Hare AM, Hotchkiss JR, Tamura MK, Larson EB, **Hemmelgarn BR**, Batten A, Covinsky KE. Interpreting treatment effects from clinical trials in the context of real world risk information: the example of end-stage renal disease prevention in older adults. *JAMA Internal Medicine* 2014;174(3):391-397.
271. Mann B, Barnieh L, Clement F, Tang K, Campbell D, **Hemmelgarn BR**, Tonelli M, Lorenzetti D, Manns BJ. Association between drug insurance cost sharing strategies and outcomes in patients with chronic disease: A systematic review. *PLOS One* 2014;9:e89168.
272. Samuel SM, Palacios-Derflingher L, Tonelli M, Manns B, Crowshoe L, Ahmed S, Jun M, Saad N, **Hemmelgarn BR**. Association between Aboriginal ethnicity and progression to kidney failure by presence and severity of albuminuria. *CMAJ* 2014;186:E86-E94.
273. Nesrallah G, Mustafa R, Clark W, Bass A, Barnieh L, Klarenbach S, Quinn RR, Shiremath S, **Hemmelgarn BR**, Ravani P, Sood M, Moist L. Canadian Society of Nephrology 2014 Clinical Practice Guideline for timing the initiation of dialysis. *CMAJ* 2014;186:112-117.
274. Barnieh L, King-Shier K, **Hemmelgarn BR**, Laupacis A, Manns L, Manns B. Views of Canadian patients on or nearing dialysis and their caregivers: A thematic analysis. *Canadian Journal of Kidney Health and Disease* 2014, 1:4.
275. Weaver R, Manns BJ, Tonelli M, Sanmartin C, Campbell DJT, Ronksley PE, Lewanszuk R, Braun T, Hennessy Deirdre, **Hemmelgarn BR**. Access to primary care and other health care use among Western Canadians with chronic conditions: a population-based survey. *CMAJ Open* 2014 DOI:10.9778/cmajo.20130045.
276. Tu K, Butt, D, Anderson L, **Hemmelgarn BR**, Quan H, Campbell N, McAlister F. Antihypertensive drug prescribing and persistence among new elderly users in Ontario. *Can J Cardiology* 2014;30(6):647-652.

277. Wiebe N, Kalrenbach SW, Allan GM, Manns BJ, Pelletier R, James MT, Bello A, **Hemmelgarn BR**, Tonelli M. Potentially preventable hospitalization as a complication of chronic kidney disease. *Am J Kidney Dis* 2014;64(2):230-238.
278. Campbell DJT, Ronksley PE, Manns BJ, Tonelli M, Sanmartin C, Weaver RG, Hennessy D, King-Shier K, Campbell T, **Hemmelgarn BR**. The association of income with health behavior change and disease monitoring among patients with chronic disease. *PLOS ONE* 2014 9(4):e94007.
279. Mustafa RA, Levin A, Akbari A, Foster J, Zimmerman D, Nesrallah G, Knoll GA, Rioux J, Barton J, Ruzicka M, Muirhead N, Moist L, Pannu N, McFarlane P, Klarenbach S, Samuel S, Clark WF, **Hemmelgarn BR**. The Canadian Society of Nephrology Methods in Developing and Adapting Clinical Practice Guidelines: A review. *Canadian Journal of Kidney Health and Disease* 2014;1:5.
280. Manns BJ, Scott-Douglas N, Tonelli M, Ravani P, LeBlanc M, Dorval M, Holden R, Moist L, Lok C, Zimmerman D, Au F, **Hemmelgarn BR**. The prevention of dialysis catheter lumen occlusion with rt-PA versus heparin (Pre-CLOT): A cost effectiveness analysis alongside a randomized trial. *J Am Soc Nephrol* 2014; 25:2887-2895.
281. Weaver R, Hemmelgarn BR, Rabi D, Sargious P, Edwards A, Manns B, Tonelli M, James M. Association between participation in a brief diabetes education program and glycaemic control in adults with newly diagnosed diabetes. *Diabet Med* 2014;31:1610-4.
282. Manns B, **Hemmelgarn BR**, Lillie E, Crowe S, Cyr A, Gladish M, Large C, Silverman H, Toth B, Wolfs W, Laupacis A. Setting research priorities for patients on or nearing dialysis. *CJASN* 2014;9(10):1813-21.
283. Bresee L, Knudtson M, Zhang J, Crowshoe L, Ahmed S, Tonelli M, Ghali W, Quan H, Manns B, Fabreau G, **Hemmelgarn BR**. Access to and outcomes after coronary angiography for First Nations People with acute myocardial infarction. *CMAJ* 2014;186(10):E372-80.
284. Tricco AC, Antony J, Angeliki VA, Ashoor H, Hutton B, **Hemmelgarn BR**, Moher D, Finkelstein Y, Gough K, Straus SE. Safety and effectiveness of antiretroviral therapies for HIV-infected women and their infants and children: protocol for a systematic review and network meta-analysis. *Systematic Reviews* 2014, 3:51.
285. Ruzicka M, Quinn RR, McFarlane P, **Hemmelgarn BR**, Prasad GVR, Feber J, Nesrallah G, MacKinnon M, Tangri N, McCormick B, Tobe S, Blydt-Hansen T, Hiremath S. Canadian Society of Nephrology commentary on the 2011 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD. *Am J Kidney Dis* 2014;63:869-887.
286. Ward DR, Moist LM, MacRae JM, Scott-Douglas N, Zhang J, Tonelli M, Lok C, Soroka S, **Hemmelgarn BR**. Risk factors associated with hemodialysis central venous catheter malfunction: a retrospective analysis of a randomized controlled trial. *Canadian Journal of Kidney Health and Disease* 2014;1:15.
287. Clement FM, Chen G, Khan N, Tu K, Campbell NR, Smith M, Quan H, **Hemmelgarn BR**, McAlister FA. Primary care physician visits by patients with incident hypertension. *Can J Cardiol* 2014;30:653-660.
288. Iansavichus AV, Hildebrand AM, Haynes RB, Wilczynski NL, Levin A, **Hemmelgarn BR**, Tu K, Nesrallah G, Nash D, Garg AX. High-performance information search filters for chronic kidney disease content in PubMed, Ovid Medline and Embase. *Am J Kidney Dis* 2014;65(1):26-32.
289. Tricco AC, Cogo E, Angeliki VA, Soobiah C, Hutton B, **Hemmelgarn BR**, Moher D, Finkelstein Y, Straus SE. Comparative safety of anti-epileptic drugs among infants and

- children exposed in-utero or during breastfeeding: protocol for a systematic review and network meta-analysis. *Systematic Reviews* 2014; 3:68.
290. Faruque LI, Battistella M, Reiman T, **Hemmelgarn BR**, Thomas C, Tonelli M. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer. *PLoS One* 2014 Jul 2;9(7):e101145 doi: 10.1371
 291. Manns B, Barrett B, Evans M, Garg A, **Hemmelgarn BR**, Kappel J, Klarenbach S, Madore F, Parfrey P, Samuel S, Soroka S, Suri R, Tonelli M, Wald R, Walsh M, Zappitelli M. Establishing a national knowledge translation and generation network in kidney disease: the Canadian KidNey Knowledge TraNslation and Generation NeTwork. *Canadian Journal of Kidney Health and Disease*, 2014 1:2.
 292. Bello A, Levin A, Manns BJ, Feehally J, Drueke T, Faruque L, **Hemmelgarn BR**, Kernahan C, Mann J, Klarenbach S, Remuzzi G, Tonelli M. Effective chronic kidney disease care in European countries: challenges and opportunities for health policy. *Am J Kidney Dis* 2014 65(1):15-25.
 293. Nicholl D, Hanly P, Poulin M, **Hemmelgarn BR**, Sola D, Ahmed SB. Evaluation of CPAP therapy on the renin-angiotensin system activity in obstructive sleep apnea. *Am J Resp Critical Care Med* 2014;190(5):572.80.
 294. De Koning L, Henne D, Woods P, **Hemmelgarn BR**, Naugler C. Sociodemographic correlates of Vitamin D test utilization in Calgary, Alberta. *BMC Health Services Research* 2014;14:339.
 295. Mann MC, Exner DV, **Hemmelgarn BR**, Hanley D, Turin TC, MacRae JM, Ahmed SB. VITAH Trial: Vitamin D supplementation and cardiac autonomic tone – A blinded, randomized controlled trial. *BMC Nephrology* 2014;15:129.
 296. Turin TC, James MT, Jun M, Tonelli M, Coresh J, Manns BJ, **Hemmelgarn BR**. Short-term change in eGFR and risk of cardiovascular events. *J Am Heart Assoc* 2014;3(5):e000997.
 297. James MT, Dixon E, Roberts DJ, Barry R, Balint C, Bharwarni A, Buie WD, Godinez T, **Hemmelgarn BR**, Kortbeek JB, Manns BJ, Marin A, Scott-Douglas N, Stelfox HT, Pannu N. Improving prevention, early recognition and management of acute kidney injury after major surgery: results of a planning meeting with multidisciplinary stakeholders. *Canadian Journal of Kidney Health and Disease* 2014;1:20.
 298. Tricco A, Ashoor H, Antony T, Beyene J, Harrington A, Wilson C, Soobiah C, Yu C, Hutton B, Hoch J, **Hemmelgarn BR**, Majumder S, Straus SE. Safety, effectiveness and cost-effectiveness of long-acting versus intermediate-acting insulin for patients with type 1 diabetes: a systematic review and network meta-analysis. *BMJ* 2014;349:g5459.
 299. Tricco A, Antony T, Khan P, Ghassem M, Ashoor H, Blondal E, Soobiah C, Yu C, Hutton B, **Hemmelgarn BR**, Moher D, Majumder M, Straus SE. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycemic agents: A systematic review and network meta-analysis. *BMJ Open* 2014;4:e005752 doi:10.1136/bmjopen-2014-005752.
 300. Haller MC, van der Veer SN, Nagler EV, Tomson C, Lewington A, **Hemmelgarn BR**, Gallagher M, Rocco M, Obrador G, Vanholder R, Craig JC, Van Biesen W. A survey on the methodological processes and policies of renal guideline groups as a first step to harmonize renal guidelines. *Nephrol Dial Transplant*. 2014;0:1-8.
 301. Moist LM, Fenton S, Kim JS, Gill JS, Ivis F, de Sa E, Wu J, Al-Jaishi A, Sood M, Klarenbach S, **Hemmelgarn BR**, Kappel JE. Canadian Organ Replacement Register (CORR): Reflecting the past and embracing the future. *Canadian Journal of Kidney Health and Disease* 2014, 1:26.

302. Campbell DJT, Lacny SL, Weaver RG, Manns BJ, Tonelli M, Barnabe C, **Hemmelgarn BR**. Age modification of diabetes-related hospitalization among First Nation patients. *Diabetology & Metabolic Syndrome*. 2014 6:108.
303. Walker RL, Chen G, McAlister FA, Campbell NR, **Hemmelgarn BR**, Dixon E, Ghali W, Rabi D, Tu K, Jette N, Quan H. Relationship between primary care physicians visits and hospital emergency use for uncomplicated hypertension, an ambulatory care sensitive condition. *Can J Cardiol* 2014;30:1640-8.
304. Ngwakongnwi E, King-Shier KM, **Hemmelgarn BR**, Musto R, Quan H. Comparison of sampling methods for hard-to-reach francophone populations: yield and adequacy of advertisement and respondent-driven sampling. *Open Med* 2014;8(4):e120–e129
305. Leung KC, Pannu N, Tan Z, Ghali WA, Knudtson ML, **Hemmelgarn BR**, Tonelli M, James MT. Contrast-associated AKI and use of cardiovascular medications after acute coronary syndrome. *Clin J Am Soc Nephrol* 2014;9(11):1840-8.
306. Tang K, Clement F, Aramjit B, Campbell D, Barnieh L, **Hemmelgarn BR**, Tonelli M, Lorenzetti D, Manns BJ. A systematic review of value-based insurance design in chronic diseases. *Am J Managed Care* 2014;20:e229-41.
307. Samimi A, S Ramesh, Chowdhury TC, MacRae J, Sarna M, Reimer K, **Hemmelgarn BR**, Sola D, Ahmed SB. Serum uric acid level, blood pressure and vascular Angiotensin II-responsiveness in healthy men and women. *Physiological Reports* 2014; 2(12) e12235.
308. Galbraith L, Manns B, **Hemmelgarn BR**, Walsh M. The Steroids in the Maintenance of Remission of Proliferative Lupus Nephritis (SIMPL) Pilot Trial. *Canadian Journal of Kidney Health and Disease*. 2014;1:30.
309. Turin TC, Ahmed SB, Tonelli M, Manns B, Ravani P, James M, Quinn RR, Jun M, Gansevoort R, **Hemmelgarn BR**. Kidney function, albuminuria and life expectancy. *Canadian Journal of Kidney Health and Disease*. 2014;1:33.

YEAR 2015

310. Yakovenko I, Quigley L, **Hemmelgarn BR**, Hodgins D, Ronksley R. The efficacy of motivational interviewing for disordered gambling: Systematic review and meta analysis. *Addictive Behaviors* 2015;43:72-82.
311. Tricco A, Soobiah C, Hui W, Antony J, Struchkov B, Hutton B, **Hemmelgarn B**, Moher D, Straus SE. Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT₃) receptor antagonists: A systematic review. *BMC Pharmacology and Toxicology* 2015;16:1.
312. Tong A, Chando S, Crowe S, Manns B, Winkelmayer WC, **Hemmelgarn B**, Craig JC. Research priority setting in kidney disease: a systematic review. *Am J Kidney Dis* 2015;65(5):674-83.
313. Jun, M, James M, Manns B, Quinn R, Ravani P, Tonelli M, Perkovic V, Winkelmayer W, Ma Z, **Hemmelgarn BR**. The association between kidney function and major bleeding in older adults with atrial fibrillation initiating warfarin therapy: a population-based observational study. *BMJ* 2015 in **press**.
314. Barnieh L, Jun M, Laupacis A, Manns B, Hemmelgarn BR. Determining research priorities through partnership with patients: an overview. *Seminars in Dialysis* 2015; 28(2):141-6.
315. Peng M, Chen G, Lix L, McAlister F, Tu K, Campbell N, **Hemmelgarn BR**, Svenson L, Quan H. Refining hypertension surveillance to account for potentially misclassified cases. *PLOS ONE* 2015;10(3):e0119186.

316. Chowdhury TT, **Hemmelgarn BR**. Evidence-based decision making: Utilization of administrative databases for health services research. *Methods Mol Biol*. 2015;1281:469.
317. Mann M, Hobbs A, **Hemmelgarn BR**, Ahmed S, Roberts D, Rabi D. Effect of oral vitamin D analogues on mortality and cardiovascular outcomes among adults with chronic kidney disease: A meta-analysis. *Clin Kidney J* 2015;8:4108.
318. Barnabe C, **Hemmelgarn BR**, Jones A, Peschken C, Voaklander D, Joseph L, Bernatsky S, Esdaile J, Marshall D. Imbalance of prevalence and specialty care for osteoarthritis for First Nations People in Canada. *J of Rheumatology* 2015;42(2):323-8.
319. Blom K, Farina S, Gomez Y-D, Campbell NRC, **Hemmelgarn BR**, Cloutier L, Mackay DW, Dawes M, Tobe SW, Bolli P, Gelfer M, Mclean D, Bartlett G, Joseph L, Featherstone R, Schiffrin EL, Daskalopoulou SS. MEthods of ASsessing blood pressUre: identifying thReshold and target valuEs (MeasureBP): A Review & Study Protocol. *Current Hypertension Reports*. 2015;17(4):533.
320. Jun M, Turin TC, Woodward M, Perkovic V, Heerspink HJL, Manns BJ, Tonelli M, **Hemmelgarn BR**. The validity of surrogate outcomes for end-stage renal disease. A meta-analysis. *J Am Soc Nephrol* 2015 in **press**.
321. Thompson S, James M, Wiebe N, **Hemmelgarn BR**, Manns B, Klarenbach S, Tonelli M. Cause of death in patients with reduced kidney function. *J Am Soc Nephrol* 2015 in **press**.
322. Cunningham CT, Quan H, **Hemmelgarn BR**, Noseworthy T, Beck CA, Dixon E, Samuel S, Ghali WA, Sykes LL, Jette N. Exploring physician specialist response rates to web-based surveys. *BMC Medical Research Methodology* 2015;15:32.
323. Cunningham CT, Jette N, Li B, Dhanoa RR, **Hemmelgarn BR**, Noseworthy T, Beck CA, Dixon E, Samuel S, DeCoster C, Ghali WA, Quan H. Effect of physician alternative payment plans on administrative health data: A validation study. *CMAJ Open* 2015 in **press**.
324. Tonelli M, Wiebe N, Thompson S, Kinniburgh D, Klarenbach SW, Walsh M, Bello AK, Farugue L, Field C, Manns BJ, **Hemmelgarn BR**. Trace element supplementation in hemodialysis patients: A randomized controlled trial. *BMC Nephrology* 2015;16:52.
325. Thompson S, Wiebe N, Molzahn A, Davison S, Gill JG, **Hemmelgarn BR**, Manns BJ, Pannu N, Pelletier R, Klarenbach S, Tonelli M. Relocation of remote-dwellers living with hemodialysis: A time tradeoff survey. *Nephrol Dial Transplant* 2015 in **press**.
326. Tonelli M, Wiebe N, Fortin M, Guthrie B, **Hemmelgarn BR**, James MT, Klarenbach S, Lewanzuk R, Manns BJ, Ronksley P, Sargious P, Straus S, Quan H. Methods for identifying 27 chronic conditions: Application to administrative data. *BMC Medical Informatics and Decision Making* 2015 in **press**.
327. Kelly E, Ivers N, Zawi R, Barnieh L, Manns B, Lorenzetti D, Nicholas D, Tonelli M, **Hemmelgarn BR**, Lewanczuk R, Edwards A, Braun T, McBrien KA. Patient navigators for people with chronic disease: protocol for a systematic review and meta-analysis. *Syst Rev* 2015;4:44.
328. Lee JMC, Turin TC, Nicholl DD, Ahmed SB, Loewen A, **Hemmelgarn BR**, Azad AK. Predictors of successful completion of diagnostic home sleep testing in patients with chronic kidney disease. *Sleep and Breathing* 2015;19:669-675.
329. Tricco AC, Soobiah C, Blondal E, Veroniki A, Khan P, Vafaei A, Ivory J, Striffler L, Ashoor H, MacDonald H, Reynen E, Robson R, Ho J, Ng C, Antony J, Mrklas K, Hutton B, **Hemmelgarn BR**, Moher D, Straus SE. Comparative safety of serotonin (5-HT₃) receptor antagonists in patients undergoing surgery: A systematic review and network meta-analysis. *BMC Medicine* 2015;13:142.

330. MacRae JM, Ahmed SB, **Hemmelgarn BR**, Sun Y, Martin BJ, Anderson T. Role of vascular function in predicting arteriovenous fistula outcomes: an observational pilot study. *Canadian Journal of Kidney Health and Disease* 2015;2:19.
331. Harrison T, Wick J, Quinn R, Manns B, Jun M, Ahmed S, Tonelli C, **Hemmelgarn BR**. Patients with chronic kidney disease and their intent to use electronic personal health records. *Canadian Journal of Kidney Health and Disease* 2015 2:23.
332. Tricco A, Soobiah C, Blondal E, Veroniki AA, Khan PA, Varaei A, Ivory J, Strifler L, Ashoor H, MacDonald H, Reynen E, Robson R, Ho J, Ng C, Antony J, Mrklas K, Hutton B, **Hemmelgarn BR**, Moher D, Straus SE. Comparative efficacy of serotonin (5-HT3) receptor antagonists in patients undergoing surgery. A systematic review and meta-analysis. *BMC Medicine* 2015;13:136.
333. Tonelli M, Wiebe N, Guthrie B, James MT, Quan H, Fortin M, Klarenbach SW, Sargious P, Straus S, Lewanczuk R, Ronksley PE, Manns BJ, **Hemmelgarn BR**. Comorbidity as a driver of adverse outcomes in people with chronic kidney disease: a cohort study. *Kidney International* 2015 in **press**.
334. Weaver C, Clement F, Campbell N, James M, Klarenbach S, **Hemmelgarn BR**, Tonelli M, McBrien K. Health care costs attributable to hypertension: a Canadian population-based cohort study. *Hypertension* 2015 in **press**.
335. Renoux C, Lix L, Patenaude V, Bresee C, Paterson M, Lafrance JP, Tamim H, Mahmud S, Alsabbagh M, **Hemmelgarn BR**, Dormuth C, Ernst P. Serotonin-norepinephrine reuptake inhibitors and the risk of acute kidney injury: a cohort study of eight administrative databases and meta-analysis. *CJASN* 2015 in **press**.
336. Tong A, Manns B, **Hemmelgarn BR**, Wheeler DC, Tugwell P, Winkelmayr WC, Van Biesen W, Crowe S, Kerr PG, Polkinghorne KR, Howard K, Pollock C, Hawley CM, Johnson DW, McDonald S, Gallagher M, Urquhart-Secord R, Craig JC. Standardized outcomes in nephrology - Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. *Trials* 2015 in **press**.
337. Johnston B, Ebrahim S, Carrasco-Labra A, Furukawa R, Patrick DL, Crawford MW, **Hemmelgarn BR**, Schunemann HJ, Guyatt GH, Nesrallah G. Minimally important difference estimates and methods: A protocol. *BMJ Open* 2015 in **press**.
338. Gomez AT, Kiberd BA, Royston JP, Alfaadhel T, Soroka SD, **Hemmelgarn BR**, Tennankore KK. Partial validation of the Charlson and End-Stage Renal Disease Comorbidity Index for dialysis patients: A retrospective cohort study. *Canadian Journal of Kidney Health and Disease* 2015 in **press**.
339. Jun M, Manns B, Laupacis A, Manns L, Rehal B, Crowe S, **Hemmelgarn BR**. Assessing the extent to which current clinical research is consistent with patient priorities: a scoping review using a case study in patients on or nearing dialysis. *Canadian Journal of Kidney Health and Disease* 2015 in **press**.
340. Hennessy D, Sanmartin C, Ronksley P, Weaver R, Campbell D, Manns B, Tonelli M, **Hemmelgarn BR**. Out-of-pocket expenditures for prescription medications and cost-related non-adherence among Canadians with chronic disease. *Health Reports* 2015 in **press**.
341. Roberts J, Patten S, Wiebe S, **Hemmelgarn BR**, Jette N. Health related behaviors and comorbidity in people with epilepsy: changes in the past decade. *Epilepsia* 2015 in **press**.

Collaborative Publications:

1. Gansevoort Rt, Matsushita K, can der Velde M et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes in both general and high risk population. A collaborative meta-analysis of general and high-risk population cohorts. *Kidney Int* 2011 Feb 2.

Review Articles / Commentaries / Editorials:

1. Culeton BF, **Hemmelgarn BR**. Is chronic kidney disease a cardiovascular risk factor? *Seminars in Dialysis* 2003;16:95-100.
2. Culeton BF, **Hemmelgarn BR**. Inadequate treatment of cardiovascular disease and cardiovascular disease risk factors in dialysis patients: A commentary. *Seminars in Dialysis* 2004;17:342-345.
3. **Hemmelgarn BR**. End stage renal disease among Aboriginal People. *Clin Invest Med* 2006;29:383-387.
4. Pannu N, **Hemmelgarn BR**. The acute kidney injury to chronic kidney disease continuum: comment on "The magnitude of acute serum creatinine increase after cardiac surgery and the risk of chronic kidney disease, progression of kidney disease and death"/ *Arch Intern Med* 2011;171:233-4. (invited editorial).
5. James MT, Tai DJ, Strippoli GFM, MacRae JM, Tonelli M, Manns BJ, **Hemmelgarn BR**, Ravani P. Vascular access type for patients on chronic haemodialysis. *Cochrane Database of Systematic Reviews*, Issue. Art No.: DOI: 2011.
6. Turin TC, **Hemmelgarn BR**. Change in kidney function over time and risk of adverse outcomes: Is an increasing eGFR harmful? *Clin J Am Soc Nephrol* 2011;6:1805-1806. (invited editorial)
7. James MT, Tai DJ, Strippoli GFM, MacRae JM, Tonelli M, Manns BJ, **Hemmelgarn BR**, Ravani P. Vascular access type for patients on chronic haemodialysis. *Cochrane Database of Systematic Reviews* 2011, Issue 9. Art. No.:CD009299. DOI:10.1002/14651858.CD009299
8. Turin TC, **Hemmelgarn BR**. Improvement in kidney function: a real occurrence. *J Am Soc Nephrol* 2012;23:575-577. (invited editorial).
9. **Hemmelgarn BR**, Manns BJ, Tonelli M. A decade after the KDOQI CKD Guidelines – Perspectives from Canada. *Am J Kidney Dis* 2012;60:723-724. (invited editorial).
10. Ahmed SB, Mann M, **Hemmelgarn BR**. Even mild kidney dysfunction is an important cardiovascular risk predictor: Implications and challenges. *Can J Cardiol* 2013;29:1371-3 (invited editorial).
11. **Hemmelgarn BR**, Zhang J, Manns BJ, Tonelli M. Multidisciplinary care and immortal time bias. *Kidney Int* 2013 in **press**.
12. Jun M, **Hemmelgarn BR**. Automated estimated GFR reporting and late referral: Are we expecting automatic benefits? *Am J Kidney Dis* 2014;64:319-321 (invited editorial).

iii. Book Chapters:

1. Elliott MJ, O'Hare AM, **Hemmelgarn BR**. Care of the older adult with chronic kidney disease. pp XX - XX in Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu ASL (eds) *Brenner & Rector's The Kidney*, 10th Edition. Elsevier 2014.

2. Panju A, **Hemmelgarn BR**, Nishikawa J, Cook D, Kitching A. A critical appraisal of the cardiovascular history and physical examination. In S. Yusuf et al (Eds), Evidence Based Cardiology. Second Edition. London:BMJ Books, 2003.

iv. **Abstracts Published:**

Underline indicates trainee for whom I provided research supervision.

1. Dickson G, **Hemmelgarn BR**, Irvine J. Health Science Programs for Native Students. Eighth International Congress on Circumpolar Health, Whitehorse, Yukon, 1990. Conference Proceedings.
2. **Hemmelgarn BR**. The relationship between specified factors and role strain in employed mothers. Women's Health Issues Nursing Conference, Winnipeg, Manitoba, 1990. Conference Proceedings.
3. **Hemmelgarn BR**, Laing G. The relationship between identified factors and perceived role strain in employed mothers. San Diego: Sociological Abstracts Inc., 1991.
4. **Hemmelgarn BR**, Laing G. Role strain in employed mothers. Second International Conference on Family Nursing. Portland, Oregon, 1991. Conference Proceedings.
5. Ernst P, **Hemmelgarn BR**, Suissa S, McNutt M, Habbick B, Cockcroft D, Buist AS, Rebuck AS, Horwitz, RI, Spitzer WO. Clinical adjustment for asthma severity in the relationship between beta-agonist use and asthma death and near death. Am Rev Respir Dis 1991;145:A299.
6. **Hemmelgarn BR**, Saralegui S, Ernst P. Airways hyperresponsiveness and atopy in Inuit schoolchildren. European Respiratory Conference, Nice, France, 1994. Conference Proceedings.
7. **Hemmelgarn BR**, Blais L, Ernst P, Suissa S. Theophylline and β -agonist use: the risk of cardiovascular death in asthma. 11th International Conference on Pharmacoepidemiology, Montreal, 1995. Conference Proceedings.
8. **Hemmelgarn BR**, Ghali WA, Quan H, Taub KJ, Knudtson ML. Survival and revascularization rates following cardiac catheterization in dialysis vs non-dialysis patients. J Am Soc Nephrol 1999;10:243A.
9. **Hemmelgarn BR**, Ghali WA, Quan H, Taub KJ, Knudtson ML. Prognosis after cardiac catheterization in patients with non-dialysis dependent renal insufficiency. J Gen Intern Med 1999;14(supp 2);38.
10. **Hemmelgarn BR**, Ghali WA, Southern D, Knudtson ML. The survival benefit of coronary artery bypass grafting in patients with kidney disease. J Am Soc Nephrol 2003;14:676A.
11. **Hemmelgarn BR**, Ghali WA, Southern D, Humphries KH, Knudtson ML. Association between level of kidney function and survival after cardiac catheterization. J Am Soc Nephrol 2003;14:676A.
12. **Hemmelgarn BR**, Culleton BF, McLaughlin KJ, Southern D, Mortis GP, Ghali WA. The prevalence of kidney dysfunction in a community-based elderly population. J Am Soc Nephrol 2003;14:193A.
13. Culleton BF, **Hemmelgarn BR**, Mortis G, Taub KJ. Exposure to a multidisciplinary clinic improves anemia parameters in patients with chronic kidney disease. J Am Soc Nephrol 2003;14:793A.

14. Culleton BF, **Hemmelgarn BR**, Southern D, McLaughlin K, Mortis G, Larsen E, Ghali WA. Prevalence of anemia by glomerular filtration rate in a community dwelling elderly population. *J Am Soc Nephrol* 2003;14:456A.
15. McLaughlin K, Southern D, **Hemmelgarn BR**, Norton P, Sargious P, Edwards A, Larsen E, Ghali WA. Screening for kidney disease in individuals with diabetes in Southern Alberta. *J Am Soc Nephrol* 2003;14:134A.
16. McLaughlin K, Southern D, **Hemmelgarn BR**, Norton P, Sargious P, Edwards A, Larsen E, Ghali WA. Prevalence of kidney disease in individuals with diabetes in Southern Alberta. *J Am Soc Nephrol* 2003;14:134A.
17. Quinn R, McLaughlin K, Southern D, **Hemmelgarn BR**, Norton P, Sargious P, Edwards A, Larsen E, Ghali WA. The screening for kidney disease in individuals with diabetes in Southern Alberta. Canadian Society of Nephrology Annual Meeting, Toronto, ON 2004.
18. Quinn R, McLaughlin K, Southern D, **Hemmelgarn BR**, Norton P, Sargious P, Edwards A, Larsen E, Ghali WA. The prevalence of kidney disease in individuals with diabetes in Southern Alberta. Canadian Society of Nephrology Annual Meeting, Toronto, ON 2004.
19. **Hemmelgarn BR**, Ghali WA, Southern D, Culleton BF, Knudtson ML. The survival benefit of coronary artery bypass grafting in patients with kidney disease. Canadian Society of Nephrology Annual Meeting, Toronto, ON 2004.
20. Bradley JSJ, **Hemmelgarn BR**, Gourishankar S, Tonelli M. Quality of hemodialysis care in Aboriginal patients. Canadian Society of Nephrology Annual Meeting, Toronto, ON 2004.
21. **Hemmelgarn BR**, Southern D, Manns BJ, McLaughlin K, Gao S, Mortis G, Larsen E, Ghali WA, Culleton BF. Survival among an elderly community based population with chronic kidney disease. *J Am Soc Nephrol* 2004;15:145A.
22. Gregor L, **Hemmelgarn BR**, Southern D, Gao S, Mortis G, Larsen E, Ghali WA, Culleton BF. Improved survival associated with specialized chronic kidney disease care. *J Am Soc Nephrol* 2004;15:138A.
23. Culleton BF, **Hemmelgarn BR**, Southern D, Mortis G, Ghali WA. Anemia is a mortality multiplier in elderly patients with diabetes mellitus and chronic kidney disease. *J Am Soc Nephrol* 2004;15:568A.
24. McLaughlin K, Goldstein M, Yilmaz S, Seminowich S, **Hemmelgarn BR**, Munroy M, Salazar A, Ghali WA. Estimating peri-operative risk in patients undergoing kidney transplantation. *J Am Soc Nephrol* 2004;15:746A.
25. Chou S, **Hemmelgarn BR**, Gourishankar S, Bradley JSJ, Jhangri G, Tonelli M. Racial disparities in access to the transplantation waiting list in Alberta. Canadian Society of Nephrology Annual Meeting, Calgary, AB 2005, p 83.
26. Kim KJ, Bertazzon S, **Hemmelgarn BR**, Manns B, Culleton B, Gill J, Tonelli M. Distance from renal care in Canadians commencing dialysis treatment. Canadian Society of Nephrology Annual Meeting, Calgary, AB 2005, p85.
27. **Hemmelgarn BR**, Zhang J, Manns BJ, McLaughlin K, Gao S, Mortis G, Larsen E, Ghali W, Culleton B. Survival among an elderly community based population with chronic kidney disease. Canadian Society of Nephrology Annual Meeting, Calgary, AB 2005, p88.
28. Trpeski L, Badovinac K, **Hemmelgarn BR**, Jassal V, Fenton SS. Older patients on RRT in Canada: Incidence, prevalence and patient characteristics. *J Am Soc Nephrol* 2005;16:284A
29. Trpeski L, Zhu N, **Hemmelgarn BR**, Jassal V. Treatment options and outcomes in older ESRD patients in Canada, 1994-2003. *J Am Soc Nephrol* 2005;16:731A

30. Gooch K, Zhang J, Manns B, Culleton B, **Hemmelgarn BR**. Effects of non-steroidal anti-inflammatory drugs and COXIBs on the progression of CKD. *J Am Soc Nephrol* 2005;16:327A
31. James M, Zhang J, Lyon A, **Hemmelgarn BR**. Adjustment of serum total calcium for albumin concentration: derivation of a formula for the Calgary Health Region. *J Am Soc Nephrol* 2005;16:747A
32. Thomas C, Hons RB, Scott-Douglas N, **Hemmelgarn BR**. The association between concentration of heparin locking solution and malfunction of central venous hemodialysis catheters. *J Am Soc Nephrol* 2005;16:455A
33. Chou S, **Hemmelgarn BR**, Bradley J, Gourishankar S, Tonelli M. Barriers to kidney transplantation among Aboriginal Hemodialysis patients in Alberta. *J Am Soc Nephrol* 2005;16:722A
34. Chou S, Bradley J, Gourishankar S, Tonelli M, **Hemmelgarn BR**. Quality of care among Aboriginal people undergoing hemodialysis in Alberta. *J Am Soc Nephrol* 2005;16:287A
35. Gao S, **Hemmelgarn BR**, Culleton BF, Manns BJ, Gooch K, Larsen E, McLaughlin. Do laboratory prompts increase referral of patients with chronic kidney disease. *J Am Soc Nephrol* 2006;17:617A..
36. James MT, Zhang J, Lyon AW, **Hemmelgarn BR**. Reduction in misclassification of calcium status through application of a local equation for albumin-adjusted calcium. Canadian Society of Nephrology Annual Meeting, Quebec City 2006, p 88.
37. Walsh M, Sar A, Lee D, Yilmaz S, Benediktsson B, Manns B, **Hemmelgarn BR**. Methodology and preliminary results of a study using image analysis to aid in determining the prognosis of IgA nephropathy. *J Am Soc Nephrol* 2006;17:730A.
38. Walsh M, Zhang J, Culleton BF, Manns BJ, **Hemmelgarn BR**. Specialized chronic kidney disease clinic care and risk of progressive kidney disease in elderly patients. *J Am Soc Nephrol* 2006;17:648A.
39. Chou SH, **Hemmelgarn BR**, Wiebe N, Culleton B, Manns B, Klarenbach S, Gill JS, Khan NA, Tonelli M. Survival advantage in Asian and South Asian dialysis patients in Canada. Canadian Society of Nephrology Annual Meeting, Quebec City 2006, p 115.
40. Wang W, Tonelli M, **Hemmelgarn BR**, Taub K, Johnson J, Manns BJ. Increasing small solute clearance in underdialysed large hemodialysis patients does not improve quality of life. *J Am Soc Nephrol* 2006;17:867A.
41. Lok C, Allon M, Chan C, Donnelly S, Dorval M, **Hemmelgarn BR**, Moist, L, Oliver M, Tonelli M, Stanley K. Design of the Fish Oil Inhibition of Stenosis in Hemodialysis (FISH) graft study. *J Am Soc Nephrol* 2006;18:871A.
42. Chou SH, Chiang CK, Tonelli M, Gourishankar S, **Hemmelgarn BR**. An international comparison of hemodialysis care in Asian patients. *J Am Soc Nephrol* 2006;17:882A.
43. Michaud M, **Hemmelgarn BR**, Zhang J, Tonelli M, Manns BJ, Culleton BF. Higher serum phosphate is associated with increased mortality risk in the elderly. *J Am Soc Nephrol* 2006;17:342A.
44. Chou SH, **Hemmelgarn BR**, Manns BJ, Culleton BF, Weibe N, Klarenbach S, Gill J, Tonelli M. Differences in survival and use of peritoneal dialysis among East Asian, Indo Asian and White end-stage renal disease patients in Canada. *J Am Soc Nephrol* 2006;17:423A.
45. James M, Walsh M, Tonelli M, Jayne DRW, **Hemmelgarn BR**. Mycophenolate mofetil for induction therapy of proliferative lupus nephritis: A systematic review and meta-analysis. *J Am Soc Nephrol* 2006;17:572A.

46. Gao S, Manns BJ, Culleton BF, Quan H, Tonelli M, **Hemmelgarn BR**. Access to care for Aboriginal compared to non-Aboriginal people with chronic kidney disease. *J Am Soc Nephrol* 2006;17:637A.
47. Gao S, Manns BJ, Culleton BF, Quan H, Tonelli M, **Hemmelgarn BR**. Prevalence of chronic kidney disease among Aboriginal and non-Aboriginal people in Alberta. *J Am Soc Nephrol* 2006;17:637A.
48. Deyell MW, Zhang J, Ross DB, Ghali WA, **Hemmelgarn BR**. Timing of coronary artery bypass surgery following non-ST elevation acute coronary syndrome and short-term mortality. *Canadian Journal of Cardiology* 2007;23 (Supplement SC):442.
49. James M, Laupland KB, Manns BJ, Tonelli M, Culleton BF, **Hemmelgarn BR**. Association between chronic kidney disease and community-onset bloodstream infections in elderly subjects. *J Am soc Nephrol* 2007;18:774A.
50. Al-Ghamdi G, Pannu N, **Hemmelgarn B**, Klarenbach S, Wiebe N, Tonelli M. Higher dialysate potassium is associated with increased risk of death in hemodialysis patients. *Canadian Society of Nephrology Annual Meeting, Halifax NS, 2007.* p 48.
51. Deved V, **Hemmelgarn BR**. Lifestyle recommendations for patients with chronic kidney disease: A systematic review of the literature. *J Am Soc Nephrol* 2007;18:937A.
52. Conley J, James MT, MacRae J, Manns BJ, Tonelli M, Culleton BF, **Hemmelgarn BR**. Antimicrobial agents for the prophylaxis of catheter related bloodstream infections in hemodialysis patients: A systematic review and meta-analysis. *J Am Soc Nephrol* 2007;18:463A.
53. Poyah PS, Deved V, James MT, Tonelli M, **Hemmelgarn BR**. A systematic review and meta-analysis of the effect of ascorbic acid in erythropoietin-resistant anemia among hemodialysis patients. *Canadian Society of Nephrology Annual Meeting, Halifax NS, 2007.* p 79.
54. Ahmed SB, Zhang J, Culleton BF, Manns BJ, Tonelli M, **Hemmelgarn BR**. Hormone replacement therapy and progression of chronic kidney disease. *J Am Soc Nephrol* 2007;18:816A.
55. Yeates KE, Wiebe N, Sima C, Schaubel D, Holland D, **Hemmelgarn B**, Gill J, Tonelli M. A comparison of outcomes in renal transplantation among Black and White Patients in Canada. *J Am Soc Nephrol* 2007;18:669A.
56. Barnieh L, Manns, B, McLaughlin K, Klarenbach K, Yilmaz S, **Hemmelgarn BR**. Barriers to living kidney donation in eligible transplant recipients. *J Am Soc Nephrol* 2007;18:673A.
57. Khangura J, Culleton B, Zhang J, Manns B, Walsh M, Klarenbach S, Tonelli M, **Hemmelgarn BR**. Association between blood pressure measurement methods and left ventricular hypertrophy in hemodialysis patients. *Canadian Society of Nephrology Annual Meeting, London ON 2008,* p 44.
58. Schorr M, Manns B, Culleton B, Walsh M, Klarenbach S, Tonelli M, Sauve L, Wang D, **Hemmelgarn BR**. The effect of nocturnal hemodialysis vs conventional hemodialysis on nutritional status. *Canadian Society of Nephrology Annual Meeting, London ON,* p 48.
59. Deved V, Poyah P, James M, Manns, B, Tonelli M, Walsh M, **Hemmelgarn BR**. Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis. *J AM Soc Nephrol* 2008;19:322A.
60. James MT, Quan H, Tonelli M, Manns BJ, Laupland KB, **Hemmelgarn BR**. Chronic kidney disease and the risk of hospitalization with pneumonia. *J Am Soc Nephrol* 2008;19:527A.

61. Koshy SM, Garcia G, Marquez I, Renoirte G, Perez L, Salazar L, **Hemmelgarn BR**, Lloyd A, Tonelli M. Screening children in Guadalajara Mexico for chronic kidney disease on World Kidney Day. *J Am Soc Nephrol* 2008;19:533A.
62. James MT, Ghali WA, Knudtson ML, Tonelli M, Manns BJ, **Hemmelgarn BR**. Incidence of acute kidney injury post-coronary angiography. *J Am Soc Nephrol* 2008;19:576A.
63. Deved V, Altabbaa G, James MT, **Hemmelgarn BR**. Growth hormone treatment in end-stage renal disease patients with malnutrition: A systematic review and meta-analysis. *J Am Soc Nephrol* 2008;19:605A.
64. Tai DJ, Lim TW, James MT, **Hemmelgarn BR**. The effect of ACE inhibition or Angiotensin Receptor Blockade on left ventricular mass in hemodialysis patients: A systematic review and meta-analysis. *J Am Soc Nephrol* 2008;19:721A.
65. Jain AK, Akbari A, Cuerden M, **Hemmelgarn BR**, et al. Impact of estimated glomerular filtration rate reporting on nephrologist consults. *J Am Soc Nephrol* 2008;19:763A.
66. Deved V, Altabbaa G, **Hemmelgarn BR**. Growth hormone treatment in patients with end-stage renal disease: A systematic review and meta-analysis. Canadian Society of Nephrology Annual Meeting, Edmonton AB 2009, p16.
67. James MT, Ghali WA, Knudtson M, Faris P, Tonelli M, Pannu N, Klarenbach S, Manns BJ, **Hemmelgarn BR**. Effect of acute kidney injury on progression of chronic kidney disease following coronary angiography. Canadian Society of Nephrology Annual Meeting, Edmonton AB 2009, p18.
68. Ahmed SB, Muruve D, MacRae JM, Sola DY, **Hemmelgarn BR**. Vitamin D status predicts the plasma renin activity response to angiotensin II challenge. Canadian Society of Nephrology Annual Meeting, Edmonton AB 2009, p43.
69. **Hemmelgarn BR**, Zhang J, Manns B, Tonelli M, Klarenbach S, Culleton B, Krause R, Thorlacius L, Ravani P. Impact of GFR reporting on rate of new nephrology visits. World Congress of Nephrology, Milan Italy 2009.
70. Ahmed SB, Muruve DA, MacRae JM, Sola DY, **Hemmelgarn BR**. Vitamin D status and the renin angiotensin system in healthy humans. *J Am Soc Nephrol* 2009;
71. Sarna M, **Hemmelgarn BR**, Muruve DA, MacRae JM, Sola DY, Ahmed SB. The effect of Cyclooxygenase 2 inhibition on hemodynamic function and the renin angiotensin system in healthy humans. *J Am Soc Nephrol* 2009.
72. Tai DJ, Lim TW, James MT, **Hemmelgarn BR**. The effect of ACE inhibition or angiotensin receptor blockade on cardiovascular events in hemodialysis patients: A systematic review and meta-analysis. *J Am Soc Nephrol* 2009.
73. Hochman JS, Ronksley PE, **Hemmelgarn BR**, Err L, Beaulieu M, MacRae JM. Maintenance of hepatitis B antibody response in hemodialysis patients. *J Am Soc Nephrol* 2009.
74. Jain AK, Akbari A, Cuerden M, Hemmelgarn BR, Huo C, McLeod I, Loiver MJ, Ping L, Quinn RR, Tonelli M, Garg AX. eGFR reporting increased the use of kidney protective medications in the population of Southwestern Ontario with CKD. *J Am Soc Nephrol* 2009.
75. James MT, Ghali WA, Knudtson ML, Tonelli M, Faris P, Pannu N, Klarenbach S, Manns BJ, **Hemmelgarn BR**. Acute kidney injury and progression of chronic kidney disease following coronary angiography. *J Am Soc Nephrol* 2009.
76. Casilla VR, **Hemmelgarn BR**, Laupland KB, James MT. Risk of bone and joint infections in patients with chronic kidney disease not receiving renal replacement therapy. *J Am Soc Nephrol* 2009.

77. Conley JD, Brar S, Quan H, Manns BJ, Tonelli M, **Hemmelgarn BR**. Prevalence of chronic kidney disease in the Chinese, South Asian and White Populations of Alberta, Canada. *J Am Soc Nephrol* 2010.
78. Samuel SM, **Hemmelgarn BR**, Tonelli M, Nettel-Aguirre A, Soo A, Clark CG, Alexander RT, Foster BJ. Renal allograft loss during transfer of care to adult healthcare services in canadian pediatric renal transplant patients. *J Am Soc Nephrol* 2010.
79. Matsushita K, Tonelli M, Lloyd A, Levey AS, Coresh J, **Hemmelgarn BR**. Risk implications of the CKD-EPI creatinine GFR equation compared to the MDRD study equation. *J Am Soc Nephrol* 2010.
80. Ayyalasomayajula B, **Hemmelgarn BR**, Wiebe N, Tonelli M. GIS Techniques to optimize locations of New Nephrology Clinic for remote areas. *J Am Soc Nephrol* 2010.
81. Casilla VR, **Hemmelgarn BR**, James MT. Epidemiology and microbiology of joint infections in chronic kidney disease. *J Am Soc Nephrol* 2010.
82. Thomson B, Zhang J, MacRae JM, Manning MA, **Hemmelgarn BR**. Evaluation of a warfarin nomogram for anticoagulation in hemodialysis patients. *J Am Soc Nephrol* 2010.
83. Bello AK, **Hemmelgarn BR**, Lloyd A, Klarenbach S, James MT, Manns BJ, Tonelli M. Association between estimated Glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes: a longitudinal population-based study. *J Am Soc Nephrol* 2010.
84. James MT, **Hemmelgarn BR**, Wiebe N, Pannu NI, Manns BJ, Klarenbach S, Tonelli M. Glomerular-filtration rate, proteinuria, and the incidence and outcomes of acute kidney injury. *J Am Soc Nephrol* 2010.
85. Alexander RT, Foster BJ, Tonelli M, Soo A, Nettle-Aguirre A, **Hemmelgarn BR**, Samuel SM. Survival of neonates, infants and toddlers commencing renal replacement therapy. *J Am Soc Nephrol* 2010.
86. Samuel SM, Tonelli M, Foster BJ, Nettel-Aguirre A, Alexander RT, Soo A, **Hemmelgarn BR**. Death, dialysis and renal transplantation among aboriginal children with kidney failure in Canada. *J Am Soc Nephrol* 2010.
87. Ward D, Novak EM, Brar S, **Hemmelgarn BR**. The chronic disease nephropathy prevention clinic in Siksika Nation: A quality improvement project. *J Am Soc Nephrol* 2010.
88. Elliott MJ, Ronksley PE, Clase CM, Ahmed SB, **Hemmelgarn BR**. Acute management of patients with hyperkalemia: A systematic review. *J Am Soc Nephrol* 2010.
89. Sarna MA, **Hemmelgarn BR**, Muruve DA, MacRae JM, Sing S, Shi Y, Sola DY, Ahmed SB. The effect of cyclooxygenase- 2 inhibition on systemic and renal hemodialysis function and the rennin angiotensin system in healthy humans. *J Am Soc Nephrol* 2010.
90. Scobie KI, Muruve DA, Chin R, Trpkov K, Wang W, **Hemmelgarn BR**. Association between renal tubular expression of alpha five integrin and kidney failure. *J Am Soc Nephrol* 2010.
91. Barnieh L, Manns BJ, Klarenbach S, McLaughlin K, Yilmaz S, **Hemmelgarn BR**. Cost analysis of recipients of Renal Transplant: A comparison of living and deceased donor kidneys. World Congress of Nephrology, Vancouver BC, 2011.
92. Ahmed SB, Ronksley P, **Hemmelgarn BR**, Tsai W, Manns BJ, Tonelli M, Klarenbach S, Chin R, Clement F, Hanly P. Nocturnal hypoxia and loss of kidney function. World Congress of Nephrology, Vancouver BC, 2011.
93. Bello A, **Hemmelgarn BR**, Li M, Manns BJ, Ayyalasomayajula B, Klarenbach S, Tonelli M. Residence location, quality of care and adverse outcomes in diabetic subjects with CKD. World Congress of Nephrology, Vancouver BC, 2011.

94. Nicholl D, **Hemmelgarn BR**, Muruve D, Singh S, Sola D, Ahmed SB. The role of repletion of Vitamin D on blood pressure and rennin angiotensin system activity in humans. World Congress of Nephrology, Vancouver BC, 2011.
95. James M, Ghali W, Knudtson M, Tonelli M, Faris P, Manns BJ, Galbraith D, Pannu N, Klarenbach S, **Hemmelgarn BR**. Early invasive management of acute coronary syndromes and renal outcomes. World Congress of Nephrology, Vancouver BC, 2011.
96. Manning M, James M, Samuel S, Ghali W, Tonelli M, Knudtson M, Manns BJ, Faris P, Klarenbach S, Pannu N, **Hemmelgarn, BR** Acute kidney injury and adverse clinical outcomes following coronary angiography: a systematic review and meta-analysis. World Congress of Nephrology, Vancouver BC, 2011.
97. Manns BJ, Culleton BF, Tonelli M, Faris P, McLaughlin K, Gooch K, Taub K, Chin R, **Hemmelgarn BR**. A cluster randomized trial of an eGFR management laboratory prompt in chronic kidney disease. World Congress of Nephrology, Vancouver BC, 2011.
98. Turin T, Ravani P, James M, Manns BJ, Tonelli M, Quinn R, Klarenbach S, **Hemmelgarn BR**. Proteinuria and progression of kidney fuction among patients with chronic kidney disease. World Congress of Nephrology, Vancouver BC, 2011.
99. Nicholl D, Ahmed SB, Loewen A, **Hemmelgarn BR**, Sola D, Beecroft J, Hanly P. Prevalence of sleep apnea and nocturnal hypoxemia in chronic kidney disease. World Congress of Nephrology, Vancouver BC, 2011.
100. Samuel S, **Hemmelgarn BR**, Alexander T, Nettel-Aguirre, Foster B. Soo An, Tonelli M. Association between distance from renal care center and death in pediatric end-stage renal disease patients. World Congress of Nephrology, Vancouver BC, 2011.
101. Klarenbach S, Pauly RP, Walsh M, Tonelli M, Lee H, **Hemmelgarn BR**, Manns BJ. Economic evaluation of frequent home nocturnal hemodialysis based on a randomized trial. J Am Soc Nephrol 2011;22:22A
102. Elliott MJ, Tonelli M, Manns BJ, Kline G, James MT, Soo A, Hemmelgarn BR. Fracture risk is not increased in patients with chronic kidney disease. J Am Soc Nephrol 2011;22:44A.
103. Chowdhury T, Coresh J, Tonelli M, Stevens PE, **Hemmelgarn BR**. Association between change in eGFR and mortality. J Am Soc Nephrol 2011;22:46A.
104. Mann MC, **Hemmelgarn BR**, Exner D, Sola DY, Chowdhury T, Ahmed SB. Vitamin D status and the cardiac autonomic response to Angiotensin II in health humans. J Am Soc Nephrol 2011;22:160A.
105. Mann MC, **Hemmelgarn BR**, Exner D, Sola DY, Chowdhury T, Ahmed SB. Vitamin D supplementation and the cardiac autonomic response to Angiotensin II in vitamin D deficient humans. J Am Soc Nephrol 2011;22:163A
106. James MT, Tonelli M, Pannu N, Klarenbach S, Manns BJ, **Hemmelgarn BR**. Early invasive management of acute coronary syndrome and renal outcomes. J Am Soc Nephrol 2011;22:183A.
107. Zalucky A, Nicholl D, Mann, M, **Hemmelgarn BR**, Sola DY, Ahmed SB. Fat distribution and regulation of the rennin angiotensin system in healthy humans. J Am Soc Nephrol 2011;22:284A.
108. Mann M, **Hemmelgarn BR**, Exner D, Sola DY, Chowdhury T, Ahmed SB. Impact of gender and age on the cardiac autonomic response to Angiotensin II in healthy humans. J Am Soc Nephrol 2011;22:297A.

109. Samuel S, **Hemmelgarn BR**, Foster BJ, Alexander RT, Soo A, Nettel-Aguirre A, Tonelli M. Residence location and likelihood of transplantation among pediatric patients with end-stage renal disease. *J Am Soc Nephrol* 2011;22:320A.
110. Sarna M, MacRae JM, **Hemmelgarn BR**, Muruve DA, Sola DY, Ahmed SB. The impact of gender on arterial stiffness and the renin angiotensin system in healthy humans. *J Am Soc Nephrol* 2011;22:350A.
111. Nicholl D, **Hemmelgarn BR**, Chowdhury T, MacRae JM, Muruve DA, Sola DY, Ahmed SB. Urinary albumin and protein excretion are associated with increased vascular renin-angiotensin system activity in healthy humans. *J Am Soc Nephrol* 2011;22:351A.
112. Ali A, Nicholl D, **Hemmelgarn BR**, MacRae JM, Sola DY, Ahmed SB. Vitamin D status arterial stiffness and the renin angiotensin system in healthy humans. *J Am Soc Nephrol* 2011;22:355A.
113. Wang X, Chun J, Soo A, Ahmed SB, Trpkov K, **Hemmelgarn BR**, Muruve DA. Association of NLRP3 gene expression with human IgA nephropathy progression. *J Am Soc Nephrol* 2011;22:433A.
114. Nicholl D, Ahmed SB, Loewen AH, **Hemmelgarn BR**, Sola DY, Beecroft JM, Chowdhury T, Hanly P. Clinical presentation of sleep apnea in patients with chronic kidney disease. *J Am Soc Nephrol* 2011;22:683A.
115. Tai D, Ahmed SB, **Hemmelgarn BR**, MacRae JM. The effect of pneumatic compression devices on hemodynamic parameters in hemodialysis patients: a randomized crossover trial. *J Am Soc Nephrol* 2011;22:811A.
116. Cepoiu-Martin M, Tam H, Maxwell CJ, Drummond N, Ronksley P, **Hemmelgarn BR**. The effect of dementia case-management in community-dwelling individuals with dementia on resource utilization: A systematic review and meta-analysis. *Alzheimer's & Dementia* 2012;8:567.
117. Majumdar SR, Hemmelgarn BH, Lin M, McBrien K, Manns BJ, Tonelli M. Severe hypoglycemia and adverse events in older people with or without diabetes: population-based cohort study. *Diabetes*. 2013; 62 (suppl 1): A102.

v. Communications – technical reports

1. Accompanado R, Habbick B, **Hemmelgarn BR**. Investigation of water-borne diseases on Indian reserves. Department of Community Health & Epidemiology: University of Saskatchewan, Saskatoon. 1991.
2. **Hemmelgarn BR**, Edouard L, Habbick B, Feather J. Duplication of well-baby services. Department of Community Health & Epidemiology: University of Saskatchewan. 1991. ISBN # 0-88880-256-0.
3. Klarenbach S, Tonelli M, **Hemmelgarn BR**, Jindal KK. Diabetes and Kidney Disease in Alberta: In Alberta Diabetes Atlas 2007: Institute of Health Economics. 2007:83-94.
4. **Hemmelgarn BR**, Toth EL, King M, Crowshoe L, Ralph-Campbell K. Diabetes and First Nations People in Alberta: In Alberta Diabetes Atlas 2007: Institute of Health Economics. 2007:127-140.
5. Oster RT, **Hemmelgarn BR**, Toth EL, King M, Crowshoe L, Ralph-Campbell K. Diabetes and the Status Aboriginal population in Alberta: In Alberta Diabetes Atlas 2009: Institute of Health Economics. 2009:189-212.
6. Klarenbach S, **Hemmelgarn BR**, Jindal KK, Tonelli M. Diabetes and Kidney Disease in Alberta: In Alberta Diabetes Atlas 2009: Institute of Health Economics. 2009:141-151.

7. Quan H, Svenson LW, **Hemmelgarn BR**. Diabetes and hypertension in Alberta: In Alberta Diabetes Atlas 2009: Institute of Health Economics. 2009:118-126.